

CURRICULUM VITAE

Personal Data

Name: Miguel Angel Villalona-Calero, M.D.

Address: Office: 1575 San Ignacio Avenue, Suite 100
Coral Gables, Florida 33146

Phone: Office: (786) 527-8024
E-mail: MiguelVil@baptisthealth.net

Date of Birth: January 1, 1961

Work History

09/15-Present Chief Scientific Officer and Deputy Director, Miami Cancer Institute, Miami, Florida.

05/15-08/15 Associate Director Translational Research, The Ohio State University Comprehensive Cancer Center, Columbus Ohio.

05/10-05/15 Director, Division Medical Oncology, Dept of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio

05/10-05/15 Section Chief Arthur James Cancer Hospital, The Ohio State University, Columbus Ohio.

09/07-05/15 Professor of Medicine, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, and Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio

09/07-05/15 Professor of Pharmacology, Department of Pharmacology, The Ohio State University College of Medicine and Public Health, Columbus, Ohio

07/04-08/15 Co-Medical Director of Clinical Research Unit, Arthur G. James Cancer Hospital, Columbus, Ohio

10/02-09/07 Associate Professor of Medicine and Lung Cancer Physician, Arthur G. James Cancer Hospital and Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio

04/99-10/02 Assistant Professor of Medicine and Lung Cancer Physician, Arthur G. James Cancer Hospital and Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio

07/95-04/99 Research Physician, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas

08/92-08/94 Physician and Director Chemotherapy Service, Pickens County Hospital, Carrollton, Alabama

Academic Appointments

- 01/16 Professor Dept of Medicine, Family Medicine and Community Health Florida international University, Miami, Florida.
- 05/10-05/15 Dorothy M. Davies Chair in Cancer Research, The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
- 05/10-05/15 Director, Division Medical Oncology, Dept of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio
- 2007-2015 Professor of Pharmacology, Department of Pharmacology, The Ohio State University College of Medicine and Public Health, Columbus, Ohio
- 2007-2015 Professor of Medicine, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio
- 2005-2007 Associate Professor of Pharmacology, Department of Pharmacology, The Ohio State University College of Medicine and Public Health, Columbus, Ohio
- 2002-2014 Director of Solid Tumor Experimental Therapeutics, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, The Ohio State University, Columbus, Ohio
- 2002-2007 Associate Professor of Medicine with Tenure, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, and Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio
- 1999-2002 Assistant Professor of Medicine, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, and Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio
- 1996-1999 Clinical Assistant Professor, University of Texas Health Science Center, San Antonio, Texas
- 1995-1996 Instructor of Medicine, University of Texas Health Science Center, San Antonio, Texas

Education

Graduate/Undergraduate:

- 1980-1985 Medical School, Universidad Nacional Pedro Henríquez Urena (U.N.P.H.U.), Santo Domingo, Dominican Republic
- 1977-1980 Pre-medical School, Universidad Nacional Pedro Henriquez Urena (U.N.P.H.U.), Santo Domingo, Dominican Republic

Fellowships:

- 2001-2002 NHMA Health Policy Leadership, New York University, Robert Wagner Graduate School of Public Service
- 1994-1995 Drug Development, Institute for Drug Development, University of Texas Health Sciences Center at San Antonio.
- 1990-1992 Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York

1989-1990 Medical Oncology, University of Minnesota Hospital & Clinics, Minneapolis, MN

Internship and Residency:

1986-1989 Internal Medicine, Kings County Hospital Center, State University of New York Health Sciences Center at Brooklyn (DMC)

Health Service:

1985-1986 Instituto Oncologico H. Pieter, Santo Domingo, Dominican Republic

Honors and Awards

Professional Recognitions:

- 2013 Fellow, American Association for the Advancement of Science.
- 2009 Recognition Plaque for Valuable Service in the Field of Oncologic Research and Dedication to the Patients with Cancer. Universidad Nacional Pedro Henriquez Urena, Health Sciences Center, School of Medicine and the UNPHU Alumni Society, Santo Domingo, Dominican Republic.
- 2008 Outstanding Example of Translational Research. N01 CM-62207. National Cancer Institute.
- 2008 Recognition Plaque for International Role in Medical Oncology, Dominican Society of Hematology/Oncology, Punta Cana, Dominican Republic
- 2005 The V Foundation/American Association for Cancer Research Translational Cancer Research Award for Scientific Excellence in the Fight Against Cancer.
- 2003 Fray Anton de Montesinos Award to the Dominican Professional of the Year in The United States, Alumni Association Universidad Autonoma de Santo Domingo, Inc., Queens, NY
- 1999 Fellow, American College of Physicians/American Society of Internal Medicine, Philadelphia, PA

Junior Faculty Awards

- 1996 ASCO/AACR Methods in Clinical Cancer Research Workshop Travel Award, Park City Utah
- 1995 The Clinical Pharmacology of Anticancer Agents Workshop Travel Award, Lansdowne Virginia

Fellowship Awards:

- 1995 National Cancer Institute, Minority Scientist
- 1995 Travel Grant Award, American Association of Cancer Research
- 1991 Travel Grant Award, American Society of Clinical Oncology

Residency Recognition:

- 1987 Second Honorable Mention, Annual Case Report Competition, Brooklyn, N.Y.

Medical School:

- 1986 First Prize, VII Congress of the Dominican Association of Pediatric Research, Garcia Cohen Foundation, Santo Domingo, DR.
- 1986 Elected to represent U.N.P.H.U. Medical School, IV Student Investigational Congress, San Juan, Puerto Rico.
- 1985 Magna Cum Laude
- 1984 Elected among the class for a Sub-Internship in U.S.A (Internal Medicine, Danbury Hospital, Danbury, CT) Sponsored by the university and given under open contest to the best two students of the class.
- 1980-1985 Member of the Honor Board of the Medical School, Average G.P.A. 3.41/4.0, and third in the class.

Pre-medical School:

- 1977-1980 Member of the Honor Board of the University (U.N.P.H.U), Average G.P.A. 3.66/4.0, and third in the class

Administrative/Professional Development Training

- Nov 7-19, 2010 Harvard School of Public Health. Leadership Development for Physicians in Academic Health Centers

Grant support:

Principal Investigator:

a. Federal/State Agency

1. 2011-2015 National Cancer Institute, N01-CM-2011-00070. HHSN261201100070C
“Early Therapeutics Development with Phase II Emphasis”
Role: Principal investigator \$6,047,915 direct costs.
2. 2010-2015 NIH/NCI R01. CA152101
Targeting somatic homologous recombination in solid tumors.
Role: Principal Investigator. \$2,556,482.
3. 2012-2015 National Cancer Institute. T32 CA165998-01
Training Hematology and Oncology Fellows in Clinical Research.
Role: Principal Investigator, \$870,166 direct costs.
4. 2009-2012 NIH/NCI ACTNOW Clinical trial 8472, Modification to N01-CM-62207ABT-888 as Monotherapy and in Combination with Mitomycin C in Patients with Solid Tumors with Deficiency in Homologous Recombination Repair.
Role: Principal investigator, \$754,737.
5. 2006-2011 National Cancer Institute, N01-CM-62207
“Early Therapeutics Development with Phase II Emphasis”
Role: Principal investigator \$5,074,367.

6. 2004-2008 National Cancer Institute, R21 CA108157
“Biomodulation of capecitabine by docetaxel in non-small cell lung cancer”
Role: Principal Investigator, \$612,950
7. 2003-2007 National Cancer Institute, R21 CA101360 “TNF Blockade in Pancreatic Cancer Patients”. Role: Principal Investigator, \$665,276
8. 2002-2006 National Cancer Institute, R21 CA92956 “Phase II randomized trial of Sequentially Administered CPT-11 and Mitomycin C in Patients with Advanced Esophageal and Stomach Cancer.” Role: Principal Investigator, \$656,376
9. 2001-2003 National Cancer Institute, R21 CA91547
“Suramin to enhance efficacy of paclitaxel and carboplatin in NSCLC”
Role: Co-Principal Investigator, P.I. Jessie Au, \$500,000
10. 1997-2003 National Cancer Institute, Research Scientist Mentored Career Development Award K01 CA76970 "Translational Research in Lung Cancer"
Role: Principal Investigator, \$810,912
11. 1995-1998 National Cancer Institute, Long-Term Minority Investigator Research Supplement, U01 CA69853-01S1 "Phase I Clinical Trials of Anticancer Agents"
Role: Principal Investigator, \$154,717

b. Peer-Reviewed Foundations/Associations

1. 2005-2010 The V Foundation-American Association for Cancer Research Translational Research Grant “Evaluating the genetics and Pharmacodynamics of EGFR Blockade in African Americans with Lung Cancer”.
Role: Principal Investigator \$300,000 plus \$300,000 matching funds

c. Institutional

- 4- 2012-2014. Pelotonia Idea Award. Combined EGFR and BRAF blockade in Patients with Advanced Malignancies and BRAF Mutant Tumors. \$150,000 direct costs

Co-Investigator:

a. Federal/State Agency

1. 2014-2015 National Cancer Institute UM1CA186712-01
“Experimental Therapeutics of Anti-cancer Agents with Phase I Emphasis”
Role: Solid Tumor lead. P.I. Mike Grever, \$4,200,000
2. 2008-2013 National Cancer Institute R21 CA121582A
“MR-predictive-assay in pre-operative lung cancer therapy: response/resectability”
Role: Co-Investigator, P.I. J. Greco. \$750,000
3. 2014-2015 National Cancer Institute K12 CA133250-04
“Translational Training Grant in Experimental Therapeutics”
Role: Faculty Mentor, PI: J Byrd \$827,653
4. 2010-2014 1U01CA152758-01. MIRNAS/UCRS: “Biomarkers for Cancer Risk, Tumor Detection,

Progression and Treatment.”

Role: Co-Investigator, PI: Croce, 1.2 calendar months

5. 2014-2016 NIH/NCI R21CA181291: “Discovery of Homologous Recombination DNA Repair Deficiency in Lung Tumor”
Role: Co-investigator/Mentor, PI: Duan, 0.36 calendar months. \$422,981.00
6. 2009-2014 T32 CA009338-35: “Oncology Training Grant”
Role: Mentor, PI: Caligiuri \$442,656
7. 2008-2013 National Cancer Institute, UO1 CA76576-01
“Phase I trials of anti-cancer agents”,
Role: Co-Investigator, P.I., Mike Grever \$1,921,216
8. 2008-2013 National Cancer Institute K12. “Translational Training Grant in Experimental Therapeutics”
Role: Faculty Mentor, PI: J Byrd \$827,653
9. 2008-2013 National Institute of Neurological Disorders and Stroke, K01NS059575
“Combination of Cliengtide and Oncolytic HSV: a toxicology study for brain tumors”
Role: Mentor. P. I. Balveen Kaur, \$2,214,430
10. 2003-2009 State of Ohio Biomedical Research and Technology Transfer Trust Fund “Comprehensive Program for the Prevention, Detection and Treatment of Lung Cancer”
Role: Co-investigator, P. I., Mike Caligiuri, \$8,000,042, cost sharing \$15,226,121
11. 2003-2008 National Cancer Institute, UO1 CA76576-01
“Phase I trials of anti-cancer agents”,
Role: Co-investigator, P.I., Mike Grever \$1,921,216
12. 2002-2004 National Cancer Institute, R21 CA92958
“Preoperative Treatment of Lung Cancer with rhuMab VEGF”
Role: Co-investigator, P.I. Greg Otterson, \$500,000
13. 1999-2000 Comprehensive Cancer Center, Arthur James Cancer Hospital and R. Solove Research Institute
Research Award “Development of a screening strategy for hypomethylating chemotherapeutic agents”
Role: Co-Principal Investigator, \$12,500, P. I. Greg Otterson.

d. Industry (31 total):

1. 2009-2014 Oncolytics. “Phase II Study of Intravenous Administration of Reovirus Serotype 3 – Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors”. Role: Principal Investigator \$217,180
2. 2011-2014 Imclone. Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available. \$424,816.
3. 2013-2015 Glaxo/SKB. A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in

combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer \$446,170

4. 2009-2012 Glaxo/Smith Kline. An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination with Paclitaxel in First-line Treatment of Subjects with Stage IIIB wet/IV Non-small Cell Lung Cancer.
Role: Institutional Principal Investigator \$202,404
5. 2005-2012 Genentech, Inc. “A phase II randomized study of OSI-774 in African American patients with advanced and previously treated non-small cell lung cancer”. Role: Principal Investigator, \$92,365.52
6. 2009-2011 AstraZeneca. “A phase II, double blind, randomized study to assess the efficiency of AZD6244 (Hyd-Sulfate) when given in combination with docetaxel, compared with placebo to AZD6244 in combination with docetaxel in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer (stage III-IV)”.
Role: Institutional Principal Investigator. \$79,180
7. 2009-2011 Bayer Healthcare Pharmaceuticals. IST000389
“A Phase II Study of Single Agent Sorafenib In Non-small cell lung cancer patients who never smoked or were former light smokers”.
Role: Principal Investigator \$119,583
8. 2008-2010 Glaxo/SmithKline “A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer”. \$154,360
Role: Institutional Principal Investigator
9. 2005-2009 Immunogen Inc.
“A Phase I, Open Label, Dose Escalation Study of Weekly Dosing with BB-10901 Followed by a Phase II Efficacy Expansion”
Role: Institutional Principal Investigator, \$163,559
10. 2004-2007 Kosan Biosciences; Principal Investigator.
“Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KOS-1584 in Patients with Advanced Solid Tumors;
Role: Institutional Principal Investigator \$279,480
11. 2004-2006 OSI Pharmaceuticals
“A Randomized Phase II Study of Single Agent Erlotinib (Tarceva™, OSI-774) versus Standard Chemotherapy in Patients with Previously Untreated Advanced NSCLC and a Poor Performance Status”
Role: Institutional Principal Investigator, \$45,500
12. 2003-2004 Millenium Pharmaceuticals
“A randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE™ alone and VELCADE™ plus Irinotecan in Patients with Relapsed or Refractory Colorectal Carcinoma”
Role: Institutional Principal Investigator, \$117,120

130. 2003-2004 Hoffman-La Roche, Kosan Biosciences
 “Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, In Patients with Non-Small Cell Lung Cancer Who Have Progressed Following Therapy for Advanced or Metastatic Disease”
 Role: Institutional Principal Investigator, \$133,150

14. 2002-2003 Pharmacia/Celgene
 “A Phase I and Pharmacological Study of Thalidomide and Celecoxib as modulators of irinotecan’s anticancer activity”
 Role: Principal Investigator, \$225,000

15. 2001-2003 Hoffmann-La Roche Inc.
 “A Phase II Study of Capecitabine and Docetaxel in previously Treated Non-Small Cell Lung Cancer Patients”
 Role: Principal Investigator, \$165,500

16. 2001-2003 Immunex Inc.
 “Phase I and biological study of etanercept and weekly docetaxel in patients with advanced solid tumors”
 Role: Principal Investigator, \$96,000

17. 2000-2002 Isis Pharmaceuticals
 “A pilot trial of ISIS 3521, an antisense inhibitor of Protein Kinase C α , combined with Gemcitabine and Cisplatin chemotherapy in patients with advanced cancer (Part 1), or advanced, previously untreated non-small cell lung cancer (Part 2). Role: Institutional Principal Investigator, \$77,500 total

18. 2001-2002 Immunex Inc.
 “A phase I feasibility study and a randomized double blinded and placebo controlled phase III study comparing etanercept, cisplatin and etoposide with cisplatin and etoposide in patients with extensive stage and chemotherapy naïve small-cell lung cancer.
 Role: Principal Investigator, \$320,000

19. 2001-2002 Immunex Inc.
 “A phase II Study of Etanercept and Gemcitabine in Patients with Advanced Stage and Chemotherapy-Naïve Pancreatic Adenocarcinoma”
 Role: Principal Investigator, \$156,000

20. 2000 Ortho Biotech Inc.
 “Randomized study of Procrit® (epoietin alfa) vs. no Procrit on clinical outcomes in chemotherapy-naïve, stage IIB/IV non-small cell lung cancer (NSCLC) patients receiving chemotherapy”
 Role: Institutional Principal Investigator, \$ 102,000

21. 1999-2000 Rhone Poulenc Rorer
 “A phase I and pharmacokinetic study of docetaxel administered weekly to patients with advanced malignancies”
 Role: Principal Investigator, \$108,000

22. 1999-2000 Hoffmann- La Roche Inc.

“A phase I study of capecitabine in combination with weekly docetaxel in patients with advanced solid tumors”

Role: Principal Investigator, \$131,138

23. 1995-1997 Hoffmann-La Roche Inc.

“A phase I study of Capecitabine (Ro 09-1978) when combined with paclitaxel in patients with advanced solid tumors”

Role: Principal Investigator, \$210,687

24. 1995-1996 Neurobiological Technologies Inc.

“The Effect of Human Corticotropin-Releasing Factor on Peritumoral Brain Edema - Pilot Study”

Role: Principal Investigator, \$51,019

25. 1995-1996 Pro-Neuron, Inc.

“Phase I Trial of a Fixed Dose of PN401 as a Rescue Agent for Escalating Doses of 5-Fluorouracil (5-FU) in the Treatment of Patients with Cancer Refractory to Standard Therapy: weekly x 3 schedule”

Role: Principal Investigator, \$98,610

26. 1996 Knoll Pharmaceutical Company

“Phase I study to determine the safety of LU 103793, every other day x 3, given every 3 weeks to patients with malignant solid tumors”

Role: Principal Investigator, \$73,360

27. 1996-1997 Knoll Pharmaceutical Company

“Phase I study to determine the safety of LU 79553, every day x 5 days, given every 3 weeks to patients with malignant solid tumors”

Role: Principal Investigator, \$391,870

28. 1996-1997 Hoffmann-La Roche Inc.

“A phase I/II study of Capecitabine (Ro 09-1978) when combined with paclitaxel in patients with breast cancer”

Role: Principal Investigator, \$180,830

29. 1996-1997 Pharma Mar

“A phase I study of ET-743, every day x 5 days, every 21 days”

Role: Principal Investigator, \$187,325

30. 1994-1996 Knoll Pharmaceutical Company

“Phase I study to determine the safety of LU 103793 as a five-minute IV infusion, daily x 5, given every 3 weeks to patients with malignant solid tumors”

Role: Principal Investigator, \$119,040

31. 1995-1997 Ilex Oncology

“Phase I trial of Crisnatol Mesylate on an increasingly Prolonged Continuous Infusion Schedule in Patients with Refractory Malignancies”

Role: Principal Investigator, \$178,925

Certifications

1985- Diplomat of the Educational Commission for Foreign Medical Graduates.
No.378-646-4, Cert No. A6137, valid indefinitely

1987- Diplomat of the Federal Licensure Examination, ID # 610101901

1993-2003 American Board of Internal Medicine No. 127932

1995-2005 ABIM/Subspecialty Board of Medical Oncology

2003-2013 American Board of Internal Medicine, Recertification

2005-2015 ABIM/Subspecialty Board of Medical Oncology, Recertification

2014-2024 ABIM/Subspecialty Board of Medical Oncology, Recertification

Meeting MOC Requirements

2008-2010 ACLS Provider, American Heart Association

2010- Leadership Development for Physicians in Academic Health Centers, Harvard School of Public Health

Licensure

1999- State of Ohio License Registration No. 75950

1995- Texas License Registration No. J7716 (inactive)

1997- Florida License Registration No. ME 75284

1992-1995 Alabama License No. 16812 (inactive)

1990-1992 New York Limited Permit No. P47870 (inactive)

1989-1992 Minnesota License No. 32357 (inactive)

Community Service

Keynote Address Speaker, Naturalization Ceremony, Statehouse, Columbus, OH, 2007

Knights of Malta's Medical Missioner, Juncalito & Santiago, Dominican Republic, 2006-2012

Mentorship/Academic Advising

a- Mentorship Activities

Methods in Clinical Cancer Research.

American Association of Cancer Research/American Society of Clinical Oncology
Vail, Colorado.
Role: Faculty, Group Leader and Speaker 2008-2011

Minorities in Cancer Research Professional Advancement Roundtable:

Navigating the road to a successful career in cancer research.
American Association for Cancer Research
Role: Mentor 2007, 2008,
2012 (co-chair)

OSU Hematology-Oncology Fellowship Steering Committee 2006-2012

b- Mentees

<u>Faculty</u>	Level of advisees/Current Position
Tanios Bekaii-Saab, MD 2003-present	Young Faculty/Assistant Professor Hem-Onc OSU, GI-Oncology Program Leader Role: Mentor and Career Advisor
Paul Monk, MD 2006-present	Young Minority Faculty/Assistant Professor, Hem-Onc GU Program OSU Role: Career Advisor (Minority)
Yiqing Xu, MD, PhD 2003-2008	Young Faculty/Assistant Professor, Maimonides, NY Role: Career Advisor
Roger Briesewitz, PhD 2006-present	Young Faculty/Assistant Professor Dept of Pharmacology OSU Role: Advisory Committee Member/Mentor
Wenrui Duan, PhD 1999-present	Post Doctoral Researcher/Research Scientist OSU. (2010-present)) Role: Mentor, Career Advisor and Laboratory Supervisor
Kari Kendra, MD 2006-present	Young Faculty/ Assistant Professor Hem-Onc, Melanoma Program OSU Role: Career Advisor
Mitch Phelps, PhD 2008-present	Young Faculty/Assistant Professor School of Pharmacy Role: Career Advisor and RC2 Application Mentor
Bhuvana Ramaswamy, MD 2008-present	Young Faculty/Assistant Professor Hem-Onc, Breast Program OSU, CO- Medical Director Clinical Trilas Office OSUCCC Role: Career Advisor and Clinical Trials Mentor
Amir Mortazavi, MD 2008-present	Young Faculty/Assistant Professor Hem-Onc, GU Program OSU Role: Career Advisor and K Grant Application Mentor
Balveen Kaur, PhD 2007-present	Young Faculty/Assistant Professor Neurosurgery, OSU Role: K01 mentor
Abraham Jacob, MD 2007-2011	Young Faculty/Assistant Professor Department of Otolaryngology, OSU Role: K01 mentor
David O'Malley, MD 2007-present	Young Faculty/Assistant Professor Department of GYN-Oncology, OSU Role: Career Development Advisor/Clinical Trials Development
Kamal Pohar, MD 2009-2010	Young Faculty/Assistant Professor Department of Urology, OSU Role: Career Development advisor, K12 application mentor
Muller Fabbri, MD, PHD 2010-2011	Research Scientist, Department of Cancer Genetics, OSU Role: K08 mentor
Feyce Peralta, MD 2006-present	Assistant Professor, Anesthesia, Northwestern University (Minority) Role: Mentor and Career Advisor

Meng Welliver, MD Assistant Professor, Radiation Oncology, OSU
2012-present Role: Mentor and career advisor

Patrick Nana-Sinkam Associate Professor, OSU (Minority)
2012-present Role: Career advisor

Fellows

Level of advisees/Current Position

Jim Maher, MD Fellow in Hematology-Oncology/Private Practice Ohio
2001-2002 Role: Continuity Clinic Mentor

Tamila Kindwall-Keller, MD Fellow in Hematology-Oncology/Assistant Professor, Case Western
2002-2004 Role: Continuity Clinic Mentor and Advisor for Academic Development

Regina Crawford, MD Fellow in Hematology-Oncology, OSU/ Assistant Professor, Duke Univ.
2003-2005 (Minority)
Role: Continuity Clinic Mentor

Padma Nadella, MD Fellow in Hematology/Oncology, OSU/Assistant Professor, Emory
2005-2007 Role: Continuity Clinic Mentor and Career Advisor

Haghighat, MD Fellow in Hematology-Oncology/Private Practice California
2006-2007 Role: Continuity Clinic Mentor

Haiming Ding, MD, PhD Postdoctoral Fellow/Research Scientist Department of Radiology
2003-2005 Role: Laboratory Supervisor

Elaine Lam, MD Fellow in Hematology-Oncology/Chief Fellow OSU
2007-2010 Role: Continuity Clinic Mentor and Advisor for Academic Development

Hiram Perez Rivas, MD Fellow in Pulmonary OSU (Minority)
2012- Role: Mentor and career advisor

Erica Bell, PhD Postdoctoral Researcher, Radiation Oncology OSU
Research Mentor

Arjun Karvala, PhD Postdoctoral Researcher, Medical Oncology, OSU
Role: Research Mentor and Laboratory Supervisor

Students

Matt Campos Co-Path Medical Student OSU (Minority)
2009 Role: Mentor and Career Advisor

Luis Rodriguez UTHSC San Antonio, TX. Graduated Medical School 1996. Residency
1995 - 1996 Internal Medicine and Oncology Washington University/Medical
Oncologist South Texas (Minority)

c- Doctoral Student (Dissertation Advisor)

Yu-Chieh Wang Exploitation and Mechanistic Validation of Drug-combination Strategies to Overcome EGFR-inhibitor resistance in NSCLC cells. The Ohio State University, Columbus, OH.

d- Doctoral Student (Dissertation Committee Member)

Haiyan Qin. Downmodulation of Cyclin D1 by Fhit: a putative tumor suppressor pathway, The Ohio State University, Columbus, OH.

e- Doctoral, pre-candidacy (Advisor)

Yu-Chieh Wang. Enhancing the antitumor activity of EGFR inhibitors with HDAC inhibitors by simultaneously targeting Akt and NR4A1 signaling in non-small-cell lung cancer, The Ohio State University, Columbus, OH.

Memberships and Associations

American Association for the Advancement of Science (Fellow)
 American Association for Cancer Research
 American College of Physicians/American Society of Internal Medicine
 American Society of Clinical Oncology
 Cancer and Leukemia Group B
 International Association for the Study of Lung Cancer
 National Hispanic Medical Association
 Ohio State University Comprehensive Cancer Center
 Sociedad Dominicana de Hematología y Oncología.

Committees Membership

a. Institutional

Chairman, Pathology Review and Infection Control Committees	
Picken's County Hospital, Carrollton Alabama	1992-1994
Member, Pain Committee	
University of Texas Health Science Center	1996-1997
Alternate Member, Scientific Review Committee	
Cancer Therapy & Research Center	1997-1999
Co-director, Women and Minorities Committee	
The Ohio State University Comprehensive Cancer Center	1999-2002
Member, Executive Committee	
The Ohio State University Comprehensive Cancer Center	1999-2006
Member, Coordinating Committee	
The Ohio State University Comprehensive Cancer Center	1999-2006
Member Clinical Scientific Review Committee	
The Ohio State University Comprehensive Cancer Center	1999-2008
Member Clinical Value Enhancement Committee	
The Ohio State University Hospital	1999-2006
Member Operating Committee MD/PhD program	
The Ohio State University	2001-2009
Minority Recruitment Coordinator MD/PhD program	
The Ohio State University	2001-2009
Member Hematology/Oncology Fellowship Steering Committee	
The Ohio State University, Dept of Medicine	2001-present

Member Clinical Trials Office Steering Committee
 The Ohio State University Comprehensive Cancer Center 2002-present
 Member Clinical Portfolio, Outreach and Affiliations Working Group
 The Ohio State University Comprehensive Cancer Center 2003-2008
 Member, Women and Minorities Committee
 The Ohio State University Comprehensive Cancer Center 2003-2006
 Member Clinical Trials Office Medical Director Search Committee
 The Ohio State University Comprehensive Cancer Center 2005-2006
 Chair Search Committee Molecular Pharmacogenetics Program
 The Ohio State University Comprehensive Cancer Center 2005-2007
 Member Search Committee Hematology/Oncology Director
 The Ohio State University Department of Medicine 2007
 Member Advisory Committee Appointments, Promotion and Tenure
 The Ohio State University, College of Medicine 2007-2010
 Member, James Medical Staff Administrative Committee
 Arthur James Cancer Hospital 2008-2009
 Member, OSU Internal Advisory Committee, Program Project “Discovery of Novel
 Anticancer Agents of Diverse Natural Origin”, PI. D. Kinghorn
 The Ohio State University 2008-present

b. National/International

American Society of Clinical Oncology

Methods in Clinical Cancer Research. (ASCO/AACR)
 Role: Faculty, Group Leader and Speaker 2008-2011
 Member, Task Force on Health Disparities
 & Work Force Diversity 2003-2005
 Member, Grants Selection Committee 2004-2005
 Roster of Cancer Experts 2005-present
 Developmental therapeutics Scientific Committee-
 Clinical Pharmacology & Experimental Therapeutics
 abstracts review committee 2013, 2014
 Track Leader 2015

American Association for Cancer Research

Member Program Committee, Phase I, II, III Adult Clinical Trials 2003
 Member, Program Committee Clinical Research Section
 Phase II and Phase III Adult Clinical trials 2008-2009
 Member, Scientific Review Committee.
 Second AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic
 Minorities and the Medically Underserved 2008-2009
 Co-Chairman AACR 2009 Annual Meeting
 Organizing Committee 2008-2009
 Methods in Clinical Cancer Research. (ASCO/AACR)
 Role: Faculty, Group Leader and Speaker 2008-2011
 Council Member, Minorities in Cancer Research 2010-2013
 Member, Scientific Review Committee,
 Third AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic
 Minorities and the Medically Underserved 2010
 Co-Chair MICR Symposium AACR 2011 Annual Meeting 2010-2011
 Co-Chair 2012 Jane Cooke Wright Lectureship 2011-2012
 (Selection Committee member 2013)

Co-Chair Fourth AACR Conference on the Science of Health Disparities
 In Racial/Ethnic Minorities and the Medically
 Underserved 2011

Co-Chair MICR Professional Advancement Roundtable 2013

Member Scientific Review Committee Clinical and Translational Research Fellowships
 2015-2016

Cancer Prevention and Research Institute of Texas
 Member Translational and Clinical Scientific Review Committee 2009-2013

Cancer and Leukemia Group B
 Member 1999-present
 Thoracic Core Committee member 2010-present

Food and Drug Administration
 Office of Orphan Products Development, Department of Health & Human Services,
 Grant Reviewer 1998

National Cancer Institute
 Manpower and Training Review Subcommittee,
 (ad-hoc reviewer) 1999, 2000
 Clinical Oncology Review Session, Ad Hoc member 2003, 2005
 Permanent Member Clinical Oncology Review Session 2007-2009
 Cancer Center Support Grant Reviewer 2010-2011
 NCI Investigational Drug Steering Committee,
 Member 2006-present
 Member, Clinical Trial Design Task Force 2006-2008
 Member, Conflict of Interest Task Force 2006-2008
 Member, Gap Analysis Task Force 2007-2009
 Co-Chair, DNA repair Task Force 2008-2011
 Member Coordinating Committee 2011- present
 Co-Chair 2012-2014
 Clinical Trials Advisory Committee (CTAC)
 Ad Hoc member 2011
 Appointed member 2012
 Member re-appointment 2015

National Cancer Centers Network Fatigue Panel
 Member Fatigue Guidelines Development Task Force 2003

National Institute of Health
 Reviewer Loan Repayment Program Proposals 2003

Southwest Oncology Group
 Member, Lung Cancer Study Group 1998-1999

Theradex
 Medical Auditor, Cancer Center Site Visit.
 NCI Surgical Branch and NCI, Developmental Therapeutics Clinic. 2012

Journals

Editorial Board:

Journal of Clinical Oncology (2007-2015)
Cancer Chemotherapy and Pharmacology (2007-current)
Clinical Cancer Research (2010-2013)
Frontiers in Oncology (2014-current) (Associate Editor)
Ecancermedalscience (2014-current)

Reviewer:

British Journal of Cancer
Cancer Research
Cancer
Cancer Chemotherapy and Pharmacology
Cancer Genetics and Cytogenetics
Chemotherapy
Clinical Breast Cancer
Clinical Cancer Research
Investigational New Drugs
International Journal of Cancer
Journal of Clinical Oncology
Journal of Clinical Pharmacology
Lung
Molecular Cancer Therapeutics
Pharmacology and Therapeutics
Cancer Prevention Research
Springerplus

Meeting Organization Leadership Role

2010-2011	Co-Chairman AACR Fourth AACR Conference on the Science of Health Disparities In Racial/Ethnic Minorities and the Medically Underserved
2008-2009	Co-Chairman of 2009 American Association of Cancer Research Meeting
2007-2009	OSU CCC/Zangmeister Cancer Center ASCO review
2007-2008	Grand Rounds OSU Comprehensive Cancer Center
2004-2005	Grand Rounds OSU Comprehensive Cancer Center
1998	Multimodality Therapy of Lung Cancer. San Antonio

Institutional and NCI-Sponsored Protocols (Chair/Institutional-Chair):

1999-2001	OSU 9947: A phase I study of CPT-11 in combination with mitomycin-C in patients with advanced malignancies. Principal Investigator (Completed)
1999-2000	OSU 9957: A phase I study of capecitabine in combination with weekly docetaxel in patients with advanced solid tumors. Principal Investigator. (Completed)
1999	OSU 9987: Phase I/II Study of G3139, a bcl-2 antisense oligonucleotide, combined with paclitaxel for the treatment of recurrent small cell lung cancer. Co-Investigator (Completed)

- 1999 OSU 9975: Randomized study of Procrit® (epoietin alfa) vs. no Procrit on clinical outcomes in chemotherapy-naïve, stage IIB/IV non-small cell lung cancer (NSCLC) patients receiving chemotherapy. Institutional Chair. (Completed)
- 2000 OSU 0009: A pilot trial of ISIS 3521, an antisense inhibitor of Protein Kinase C α , combined with Gemcitabine and Cisplatin chemotherapy in patients with advanced cancer (Part 1), or advanced, previously untreated non-small cell lung cancer (Part 2). **Principal Investigator**. (Completed)
- 2000 OSU 9985: Phase I and clinical pharmacologic study of inhaled Doxorubicin in adults with advanced solid tumors affecting the lungs. Co-Principal Investigator (Completed)
- 2000 NCI 290, OSU 00H0057: A phase I study of BMS-214662 and Paclitaxel in Patients with Advanced Malignancies. Institutional Chair. (Completed)
- 2000 NCI 2250, OSU 00H0224: A Phase I/II Study of Carboplatin/Paclitaxel/Suramin Chemotherapy in Non-Small Cell Lung Cancer. **Principal Investigator** (completed, **R21 funding**)
- 2000 00H0314, OSU 0023: Phase I and Biological Study of Etanercept and Weekly Docetaxel in Patients with Advanced Solid Tumors. **Principal Investigator** (completed)
- 2001 OSU 0026: A Phase II Study of Capecitabine and Docetaxel in Previously Treated Non-Small Cell Lung Cancer Patients. **Principal Investigator** (completed).
- 2001 01H044, OSU 0036: A phase I feasibility study and a randomized double blinded and placebo controlled phase III study Randomized Phase III Study Comparing Etanercept, Cisplatin and Etoposide with Cisplatin and Etoposide in Patients with Extensive Stage and Chemotherapy Naïve Small-Cell Lung Cancer. **Principal investigator** (completed).
- 2001 01H0102, OSU0041: A phase I/II Study of Etanercept and gemcitabine in Patients with Advanced Stage and Chemotherapy-Naïve Pancreatic Adenocarcinoma. **Principal Investigator** (completed, **R21 funding**).
- 2001 OSU-134: Phase I and Pharmaco-Biological Study of Thalidomide and Celecoxib as Modulators of Irinotecan's Anticancer Activity. **Principal Investigator**. (Completed).
- 2001 01-H0006, OSU 0151: Phase II randomized trial of Sequentially Administered CPT-11 and Mitomycin C in Patients with Advanced esophageal and Stomach Cancer." **Principal investigator** (completed, **R-21 funding**).
- 2002 OSU 0129 A Phase II Study of PEG-Camptothecin in Subjects with Small Cell Lung Cancer. Co-investigator. (Completed)

- 2002 OSU 0120 A Phase II Study of Neoadjuvant rhuMAb VEGF (Bevacizumab) in Combination with Paclitaxel and Carboplatin in Surgically Resectable Non Small Cell Lung Cancer. Co-investigator (Completed, R21 funding)
- 2003 OSU 0238, CTEP 5889. A Pilot Study of Low dose Suramin as Modulator of Docetaxel and Gemcitabine in Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC). **Principal investigator** (completed)
- 2003 OSU 0250. A Phase 2, Randomized, Open-label Study of a Single Agent CI-1033 in Patients with Advanced Non-Small Cell Lung Cancer. Co-investigator (completed)
- 2003 OSU-0317 A phase I dose escalation study of capecitabine, carboplatin and weekly paclitaxel and a Phase II trial of the combination in-patients with adenocarcinoma of unknown primary site. Co-Principal Investigator. (Completed)
- 2003 OSU-0248, A randomized, multicenter, open-label, Phase 2b Study of Velcade alone and Velcade plus irinotecan in patients with relapsed or refractory colorectal carcinoma. Institutional Principal Investigator. (completed)
- 2004 OSU-0330. A phase I dose escalation and biological study of capecitabine and mitomycin C (MMC) in-patients with gastrointestinal solid malignancies. Co-principal Investigator. (completed).
- 2004 OSU-356, A Phase II Study of Capecitabine and Docetaxel in Previously Untreated advanced Non-Small Cell Lung Cancer Patients. Co-Principal Investigator. (completed). **R21 funding as Principal Investigator.**
- 2004 OSU-0370, Phase 2 Study of KOS-862, Administered intravenously Weekly for 3 weeks every 4 weeks, in Patients with Non-Small Cell Lung Cancer who have Progressed following Initial Therapy for Advanced or Metastatic Disease. Institutional Principal Investigator. (completed).
- 2004 OSU-0421, A Randomized Phase II Study of Single Agent Erlotinib (Tarceva™, OSI-774) versus Standard Chemotherapy in Patients with Previously Untreated Advanced NSCLC and a Poor Performance Status. Institutional Principal Investigator (completed)
- 2004 OSU-0486, Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KOS-1584 in Patients with Advanced Solid Tumors. **Principal Investigator** (completed)
- 2005 OSU-0474, A Phase I, Open Label, Dose Escalation Study of Weekly Dosing with BB-10901 Followed by a Phase II Efficacy Expansion. Institutional Principal Investigator (completed)

- 2005 OSU-0443, A Phase II randomized study of OSI-774 in African American Patients with Advanced and Previously Treated Non-Small Cell Lung Cancer (NSCLC). **Principal Investigator** (completed)
- 2005 CALGB 60301 Phase I trial of BAY 43-9006 in pts w/ organ dysfunction. Institutional Principal Investigator (completed)
- 2006 CALGB 30406 A Phase II Randomized Study Of OSI-774 (Erlotinib) with or without carboplatin/paclitaxel in patients with previously untreated adenocarcinoma of the lung who never smoked, or were former light smokers. Institutional Principal Investigator (completed).
- 2008 OSU 08046, IRB 2008C0045, NCI CTEP 7003, A Phase II study of bortezomib (PS-341) for patients with advanced bronchiolo-alveolar carcinoma (BAC) or adenocarcinoma with BAC features. Institutional Principal Investigator (completed)
- 2008 OSU 07082, IRB2007C0087, Analysis of FANCD2 protein monoubiquitin status and nuclear foci formation in primary solid tumors. **Principal Investigator.** (active)
- 2008 OSU 08017, IRB2008C0079: A Phase II Study of Single Agent Sorafenib In Non-small cell lung cancer patients who never smoked or were former light smokers. **Principal Investigator.** (closed)
- 2008 OSU 7141, A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer". Institutional Principal Investigator (closed)
- 2009 OSU 8145, Phase II Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors. Oncolytics. **Principal Investigator.** (active).
- 2009 OSU 09023 An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination with Paclitaxel in First-line Treatment of Subjects with Stage IIIB wet/IV Non-small Cell Lung Cancer. Institutional Principal Investigator (completed)
- 2009 OSU 9100 (NCI 8472). ABT-888 as Monotherapy and in Combination with Mitomycin C in Patients with Solid Tumors with Deficiency in Homologous Recombination Repair. **Principal Investigator** (active)
- 2011 OSU 10152. Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available. Institutional principal Investigator (active)

Publications

Original Reports

1. Gautier Teofilo A., Imperato-McGinley Julianne, Bido Ramon A., **Villalona C. Miguel A.**, Alvarez A Francisco, Pichardo Marino. Incomplete Androgenic Insensitivity and 5 alpha reductase deficiency in the same family. Archivos Dominicanos de Pediatria, 22: 29-39, 1986
2. **Villalona-Calero Miguel A.**, Shrem Stanley S., Phelps Kenneth R., Case Report: Pneumomediastinum complicating Pneumocystis Carinii Pneumonia in a patient with AIDS. American Journal of Medical Sciences, 297(5): 328-330, 1989
3. **Villalona-Calero Miguel A.**, Ducker Thomas, Holasek Maureen, Kennedy B.J., Management of Testicular Seminoma Following Organ transplantation. Medical and Pediatric Oncology, 20:338-340, 1992.
4. Gonzales-Vela Jose, **Villalona-Calero Miguel A.**, Kennedy B.J., Extragonadal Germ Cell Tumors of the Abdomen. American Journal of Clinical Oncology, 15(4): 308-310, 1992
5. **Villalona-Calero M**, Eckardt J, Burris H, Kraynak M, Fields S, Bazan C, Lancanter J, Hander T, Goldblum R, Hammond L, Bari A, Drengler R, Rothenberg M, Hadovsky G, Von Hoff D. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Annals of Oncology, 9: 71-77, 1998.
6. **Villalona-Calero M**, Baker S D, Hammond L, Aylesworth C, Eckhardt G, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff D.D, Rowinsky E. Phase I and Pharmacokinetic Study of the Water Soluble Dolastatin 15 Analog LU103793 in patients with advanced solid malignancies. Journal of Clinical Oncology 16(8): 2770-2779, 1998.
7. Rothenberg M, Sharma A, Weiss G, **Villalona-Calero M**, Eckardt J, Aylesworth C, Kraynak M, Rinaldi D, Rodriguez G, Burris H, Eckhardt G, Stephens C, Forral K, Nichol S, Von Hoff D. Phase I trial of Paclitaxel and Gemcitabine Administered Every-2-Weeks in Patients with Refractory Solid Tumors. Annals of Oncology, 9: 733-738,1998.
8. Rowinsky E, Smith L, Wang Y, Chaturvedi P, **Villalona M**, Campbell E, Aylesworth C, Eckhardt S, Hammond L, Kraynak M, Drengler R, Stephenson J, Harding M, Von Hoff D. Phase I and Pharmacokinetic Study of Paclitaxel in Combination with Biricodar, a Novel agent that Reverses Multidrug Resistance Conferred by overexpression of Both MDR1 and MRP. Journal of Clinical Oncology, 16 (9): 2964-2976, 1998
9. Drengler R, Kuhn J, Schaaf L, Rodriguez G, **Villalona-Calero M**, Hammond L, Stephenson J, Hodges S, Kraynak M, Station B, Elfring G, Locker P, Miller L, Von Hoff D, Rothenberg M. A Phase I and Pharmacokinetic Trial of Oral Irinotecan (CPT-11) administered daily x 5 every 3 weeks. Journal of Clinical Oncology, 17 (2): 685-696,1999
10. Diab SG, Baker S, Joshi A, Burris H, Cobb P, **Villalona-Calero M**, Eckhardt SG, Weiss G, Rodriguez G, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky E. A phase I and Pharmacokinetic study of Iosoxantrone and paclitaxel in patients with advanced solid tumors. Clinical Cancer Research, 5(2):299-308, 1999

11. Eckhardt S, Rizzo J, Sweeney K, Cropp G, Baker S, Kraynak M, Kuhn, **Villalona-Calero M**, Hammond L, Weiss G, Thurman A, Smith L, Drengler R, Eckardt J, Moczygemba J, Hannah A, Von Hoff D, Rowinsky E. A Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients with Advanced Solid Tumors. Journal of Clinical Oncology, 14(4):1095-1104, 1999
12. **Villalona-Calero M**, Weiss G, Burris H, Kraynak M, Rodriguez G, Drengler R, Eckhardt G Reigner B, Moczygemba J, Ulrich Burger H, Griffin T, Von Hoff D, Rowinsky E. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. Journal of Clinical Oncology, 17(6):1915-1925, 1999
13. Britten C, Rowinsky E, Baker S, Agarwala S, Eckardt J, Barrington R, Diab S, Hammond L, Johnson T, **Villalona-Calero M**, Fraass U, Statkevich P, Von Hoff D, and Eckhardt SG. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clinical Cancer Research 5 (7): 1629-1637, 1999
14. **Villalona-Calero M**, Petit T, Kuhn J, Kraynak M, Smith L, Aylesworth C, Drengler R, Simmons C, Cobb P, Santabarbara P, Von Hoff D, Rowinsky E. Phase I and Pharmacokinetic Study of Crisnatol Mesylate on a Prolonged Infusion Schedule in Cancer Patients. Clinical Cancer Research 5 (11):3369-3378, 1999
15. **Villalona-Calero M***, Hidalgo M*, Eckhardt SG, Drengler R, Rodriguez G, Hammond L, Diab S, Weiss G, Garner A, Campbell E, Davidson K, Louie A, O'Neil J, R. Diasio, Von Hoff D, Rowinsky E. A phase I and Pharmacologic Study of PN401 and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Journal of Clinical Oncology 18(1): 167-177, 2000 *This paper has two first authors, both contributed equally to this paper
16. Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond L, **Villalona-Calero MA**, Felton S, Drengler R, Kuhn JG, Smith SL, MacDonald J, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK. A Phase I and Pharmacokinetic Study of MGI 114, a Novel Mushroom-derived Cytotoxin Administered for Five Consecutive Days Every Four Weeks. Journal of Clinical Oncology. 18(24): 4086-4097, 2000
17. **Villalona-Calero M**, Eder JP, Toppmeyer D, Allen LF, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, O'Connor L, Kufe D, Von Hoff D, and Rowinsky E. A phase I and pharmacokinetic (PK) study of LU79553, a novel bis-naphthalamide, on a daily x 5 schedule in patients with advanced solid tumors. Journal of Clinical Oncology. 19(3): 857-869, 2001
18. Rothenberg M, Kuhn J, Schaaf L, Rodriguez G, Eckhardt SG, **Villalona-Calero M**, Rinaldi D, Hammond L, Hodges S, Sharma A, Elfring G, Petit R, Miller L, Von Hoff D. A Phase I and Pharmacokinetic Trial of Irinotecan (CPT-11) Administered Every Two Weeks. Annals of Oncology 12: 1631-1641, 2001.
19. **Villalona-Calero M**, Blum J, Jones S, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky E. A Phase I study and Pharmacologic Study of Capecitabine and Paclitaxel in Advanced Breast Cancer. Annals of Oncology 12(5): 605-614, 2001.
20. Zhu W, Dai Z, Ding H, Srinivasant K, Hall J, Duan W, **Villalona-Calero M**, Plass C, Otterson G. Increased expression of unmethylated CDKN2D gene by 5-aza 2'-deoxycytidine in human lung cancer cells. Oncogene 20: 7787-7796, 2001

21. **Villalona-Calero M**, Eckhardt SG, Weiss G, Campbell E, Hidalgo M, Kraynak M, Beijnen J, Jimeno J, Von Hoff D, Rowinsky E. A Phase I And Pharmacokinetic Study of ET-743, a Novel DNA Minor Groove Binder of Marine Origin Administered as a 1-hour infusion daily x 5 Days. Clinical Cancer Research 8: 75-85, 2002.
22. Duan Wenrui, Ding H, Zhu W, Otterson G, **Villalona-Calero M**. Detection of transgene and host endogenous homologous gene expression and silencing using RT-PCR-Heteroduplex technique in transgenic animal models. Biotechniques 33: 58-66, 2002.
23. Rudin C, Otterson G, Mauer A, **Villalona-Calero M**, George C, Prange B, Tomek R, Vokes E. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, with paclitaxel in patients with chemorefractory small cell lung cancer. Annals of Oncology 13:539-45, 2002.
24. Nadella P, Shapiro C, Otterson G, Hauger M, Erdal S, Kraut E, Clinton S, Shah M, Stanek M, Monk P, **Villalona-Calero M**. Pharmaco-biologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. Journal of Clinical Oncology 20: 2616-2623, 2002.
25. Patnaik A, Rowinsky E K, **Villalona M A**, Hammond L A, Britten C D, Siu L, Goetz A, Felton S, Burton S, Valone F, Eckhardt S. G. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clinical Cancer Research 8: 2142-2148, 2002.
26. **Villalona-Calero M**, Kolesar J. Mitomycin C as a Modulator of Irinotecan Anticancer Activity. Oncology 16: 8, supp 7: 21-25, 2002
27. Duan W, Ding H, Subler M, Zhu W, Zhang H, Stoner G, Windle J, Otterson G, **Villalona-Calero M**. Lung specific expression of mutant p53 (273H) results in high frequency of lung adenocarcinoma in transgenic mice. Oncogene 21: 7831-7838, 2002.
28. Zhu W, Srinivasan K, Dai Z, Ding H, Duan W, Yee L, **Villalona-Calero M**, Plass C, Otterson G. Hypermethylation induced decrease in Sp1/Sp3 binding is associated with reduced p21^{Cip1} expression in response to depsipeptide treatment. Molecular and Cellular Biology. 23(12):4056-4065, 2003. PMID:PMC 156121
29. **Villalona-Calero M**, Guill Wientjes, Gregory A Otterson, Steven Kanter, Donn Young, Anthony Murgu, Beth Fischer, Carrie DeHoff, Danny Chen, Teng Kuang Yeh, SaeHeum Song, Michael Grever, Jessie L Au. Phase I Study of Low Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research. 9(9):3303-11, 2003.
30. Ding H, Duan W, Zhu W, Ju R, Srinivasan K, Otterson G, **Villalona-Calero M**. Mechanisms of p21^{WAF1/Cip1} Response to DNA Damage Induced by the Topoisomerase II Inhibitors Genistein and Etoposide in Human Lung Cancer Cells. Biochemical and Biophysical Research Communications. 13;305(4):950-6, 2003.
31. Venook A, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, **Villalona, M**, Marshall J, Rosner G, Ramirez J, Kastrissios H, Ratain M. A Phase I and Pharmacokinetic Study of Irinotecan in Patients with hepatic or Renal Dysfunction or with prior pelvic Radiation: CALGB 9863. Annals of Oncology. 14: 1783-1790, 2003

32. Zhu W, Hileman T, Ke Y, Wang P, Duan W, Dai Z, Tong T, **Villalona-Calero**, M, Plass C, Otterson G. 5-aza-2'-deoxycytidine activates p53/p21^{waf1/cip1} pathway to inhibit cell proliferation. The Journal of Biological Chemistry 279(15):15161-6, 2004
33. Duan W, Gao L, Druhan L, Zhu W, Otterson G, and **Villalona-Calero M**. Pirh2 , a newly identified ubiquitin protein ligase, expression in lung cancer. Journal of The National Cancer Institute. 96 (22): 1718-1721, 2004.
34. Winegarden J, Mauer A, Otterson G, Rudin C, **Villalona-Calero M**, Lanzotti V, Szeto L, Kasza K, Hoffman P, Vokes E. A Phase II study of oxaliplatin and paclitaxel in patients with advanced non-small cell lung cancer. Annals of Oncology. 15(6):915-20, 2004.
35. **Villalona-Calero M**, Ritch P, Figueroa J, Otterson G, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M, Valdivieso M, Holmlund J. A Phase I/II Study of ISIS 3521, an Antisense Inhibitor of Protein Kinase C Alpha, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non Small Cell Lung Cancer. Clinical Cancer Research. 10(8):6086-93, 2004
36. Kindwall-Keller T, Otterson G, Young D, Neki A, Criswell T, Nuovo G, Soong R, Diasio R, **Villalona-Calero, M.A**. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clinical Cancer Research 11:1870-1876, 2005
37. Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena R, Plass C, Caldes T, Mutter G, **Villalona-Calero M***, Eng C. Variability in organ-specific EGFR mutational spectra in tumor epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. British Journal of Cancer 2005 May 23;92(10):1922-6. *Co-corresponding author. PMC 2361765
38. Otterson, G.A., Lavelle, **Villalona-Calero, M.A**, Shah, M, Wei, X., Chan, K, Fischer, B, Zweibel, J, Grever, M. A Phase I Clinical and Pharmacokinetic Study of Fenretinide Combined with Paclitaxel and Cisplatin for Refractory Solid Tumors. Investigational New Drugs 2005 23(6):555-62
39. Mita A, Sweeney C, Baker S, Goetz A, Felton S, Hammond L, Patnaik A, Tolcher A, **Villalona-Calero M**, Sandler A, Chaudhuri T, Molpus K, Latz J, Johnson R, Rowinsky E, Takimoto C. A phase I and pharmacokinetic study of pemetrexed administered intravenously every 3 weeks to advanced cancer patients with impaired renal function. Journal of Clinical Oncology. January 2006 24(4):552-62
40. Monk JP, Phillips G, Waite Ross, Kuhn J, Schaaf L, Otterson G, Rhoades C, Shah M, Criswell T, Caligiuri M, **Villalona-Calero M**. Tumor necrosis factor alpha blockade improves tolerability of dose intensive chemotherapy. Journal of Clinical Oncology. April 2006 24(12):1852-9.
41. Chen D, Song S, Wientjes M.G, Yeh T, Zhao L, **Villalona-Calero M**, Otterson G, Jensen R, Grever M, Murgo A, and Au J. Non toxic suramin as a chemosensitizer in patients: Dosing nomogram development. Pharmaceutical Research 2006 Jun;23(6):1265-74
42. **Villalona-Calero M.A**, Schaaf L, Otterson G, Panico K, Duan W, Kleiber B, Shah M, Young D, Phillips G, Wu W, Kuhn J. Pharmacobiological study of thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. Cancer Chemotherapy and Pharmacology. 2007; 59(1):23-33.

43. Duan W, **Villalona-Calero MA** . RCHY1 (ring finger and CHY zinc finger domain containing 1). Atlas Genet Cytogenet Oncol Haematol. March 2006.
URL: <http://atlasgeneticsoncology.org//Genes/RCHY1ID43012ch04q21.html>
44. Mrozek E, Ramaswamy B, Young D, Rhoades C, Kendra K, Allen J, Hauger M, Watson H, Moore T, Merrimen N, Nadella P, **Villalona-Calero M**, and Shapiro C. Phase II study of weekly docetaxel and capecitabine in metastatic breast cancer patients. Clinical Breast Cancer 2006;7(2):141-5.
45. Duan W, Gao L, Wu X, Zhang Y, Otterson G, **Villalona-Calero M**. Differential response between the p53 ubiquitin-protein ligases Pirh2 and Mdm2 following DNA damage in human cancer cells. Experimental Cell Research 2006; 312(17):3370-8.
46. Ross P, Grecula J, Bekaii-Saab T, **Villalona-Calero M**, Otterson G, Magro C. Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Laser in Surgery and Medicine. 2006; 38(10):881-9
47. Otterson G, **Villalona-Calero M**, White D, Sharma S, Kris M, Gerber M, Imondi A, Ratain M, Schiller J, Sandler A, Kraut M, Mani S, Murren J. Results from a phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clinical Cancer Research. 15;13(4):1246-52, 2007
48. Bekaii-Saab T, Williams N, Plass C, **Villalona-Calero M**, Eng C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC-Cancer. 2006 Dec 6;6(1):278
49. Duan W, **Villalona-Calero MA** . MDM2 (transformed mouse 3T3 cell double minute 2, p53 binding protein). Atlas Genet Cytogenet Oncol Haematol. December 2006.
URL : <http://AtlasGeneticsOncology.org/Genes/MDM2ID115ch12q15.html>
50. Miller A, Murry D, Owzar K, Hollis D, Lewis L, Kindler H, Marshall J, **Villalona-Calero M**, Edelman M, Hohl R, Lichtman S, and Ratain M. Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients with Hepatic or Renal Dysfunction: Cancer and Leukemia Group B Study 60101. J Clin Oncol. 25(21):3055-60, 2007.
51. Duan W, Gao L, Jin D, Otterson GA, **Villalona-Calero MA**. Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice. Transgenic Research 17(3):355-66, 2008.
52. Mrozek E, Kolesar J, Young D, Allen J, **Villalona-Calero M**, and Shapiro C. Phase II Study of Sequentially administered Mitomycin-C (MMC) and Irinotecan (CPT-11) in Women with Metastatic Breast Cancer (MBC). Annals of Oncology 19(8):1417-22, 2008.
53. **Villalona-Calero M**, Otterson G, Wientjes MG, Weber F, Bekaii-Saaab T, Young D, Murgo A, Jensen R, Yeh T, Wei Y, Zhang Y, Eng C, Grever M, Au JL. Non-Cytotoxic Suramin as a Chemo-sensitizer in Patients with Advanced Non-Small Cell Lung Cancer; A Phase II Study. Annals of Oncology 19(11): 1903-9, 2008. PMCID: PMC 2733080
54. Xu Y, Kolesar J, Schaaf L, Drengler R, Duan W, Miller J, Otterson G, Shapiro C, Kuhn J and **Villalona-Calero M**. Phase I and Pharmacokinetic Study of Mitomycin C and Celecoxib as

- Potential Modulators of Tumor Resistance to Irinotecan in Patients with Solid Malignancies. Cancer Chemotherapy and Pharmacology 63(6):1073-82, 2009
55. Woyach J, Kloos R, Ringel M, Arbogast D, Collamore M, Zwiebel J, Grever M, **Villalona-Calero M** and Shah M. Lack of therapeutic effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 94(1):164-70, 2009. PMID: PMC 2630867
 56. Miller A, Murry D, Owzar K, Hollis D, Kennedy E, Abou-Alfa G, Desai A, Hwang J, **Villalona-Calero M**, Dees E, Lewis L, Fakih M, Edelman M, Millard F, Frank R, Hohl R, Ratain M. Phase 1 and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B study 60301. Journal of Clinical Oncology. 27(11):1800-5.2009. PMID: PMC 2668705
 57. Duan W, Gao L, Wu X, Hade E, Gao J, Ding H, Barsky S, Otterson G, and **Villalona-Calero M**. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS One 2009;4(5):e5563. Epub 2009 May 15. PMID: PMC 2680060
 58. Lin T, Ruppert A, Johnson A, Fischer B, Heerema N, Andritsos L, Blum K, Flynn J, Jones J, Hu W, Moran M, Mitchell S, Smith L, Wagner A, Raymond C, Phelps M, **Villalona-Calero M**, Grever M, Byrd J. A Phase II Study of Flavopiridol (Alvocidib) in Relapsed, Chronic Lymphocytic Leukemia (CLL): High Response Rates in Genetically High-Risk Disease. Journal of Clinical Oncology. 2009 Dec 10;27(35):6012-8. PMID: PMC2793044
 59. Bekaii-Saab T, Markowitz J, Eng C, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee R, Zalupski M, Dancy J, Chen H, Grever M, **Villalona-Calero M**. A multi-institutional Phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clinical Cancer Research, 2009;15(18):5895-901. PMID: PMC2774354
 60. Bekaii-Saab T, Hill M, Campbell A, Kosuri K, Thomas J, **Villalona-Calero M**. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C (MMC) in patients with gastrointestinal malignancies. Cancer Chemotherapy and Pharmacology, 2010 Apr;65(5):863-9.
 61. Duan W, Gao L, Wu X, Wang L, Nana-Sinkam P, Otterson GA, **Villalona-Calero MA**. MicroRNA 34a is an important component of PRIMA-1 induced apoptotic network in human lung cancer cells. International Journal of Cancer. 2010 Jul 15;127(2):313-20. PMID: 19921694
 62. Hamadani M, Awan F, **Villalona-Calero MA**. Malignant thymoma with immunodeficiency (Good syndrome) associated with Mucormycosis. American Journal of Clinical Oncology 2010 Feb;33(1):109
 63. Lam E, Ringel M, Kloos R, Prior T, Knopp M, Liang J, Griffin R, Hall N, Wakely P, Saji M, Snyder P, Wei L, Arbogast D, Collamore M, Wright J, Moley J, **Villalona-Calero M**, Shah M. Phase II Clinical Trial of the Multi-Kinase Inhibitor, Sorafenib, in Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology. 2010 May 10;28(14):2323-30. PMID: PMC2881718

64. Kosuri KV, Wu X, Wang L, **Villalona-Calero, MA**, Otterson GA. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun. 2010 Jan 15;391(3):1465-70. PMID:PMC2860267
65. Otterson GA, **Villalona-Calero MA**, Hicks W, Pan X, Ellerton J, Gettinger S, Murren J. Phase I/II Study of inhaled doxorubicin combined with platinum based therapy for advanced NSCLC. Clinical Cancer Research 16(8):2466-73,2010.
66. Blum W, Garzon R, Geyer S, Klisovic R, Liu S, Walker A, Havelange V, Schwind S, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine S, Chan K, Grever M, Byrd J, Bloomfield C, **Villalona-Calero M**, Croce C, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10 day schedule of decitabine: Proceedings of the National Academy of Sciences (USA). 107(16):7473-8, 2010. PMID: 20368434. PMID: PMC2867720
67. Lustberg M, Bekaii-Saab T, Young D, Otterson G, McCracken B, **Villalona-Calero M**. Phase II Randomized Study of Sequentially Administered Mitomycin C (MMC) and Irinotecan (CPT-11) in Patients with Advanced Esophageal and Gastroesophageal Adenocarcinoma. Journal of Thoracic Oncology 5 (5): 713-718, 2010. PMID: 20354452, PMID: PMC3641556
68. Shanafelt T, Zent C, Byrd J, Erlichman C, LaPlant B, Ghosh A, Call T, **Villalona-Calero M**, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N. Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL). Leukemia and Lymphoma. 2010; 51 (12):2222-9. PMID: 21054149.
69. Lam E, Wientjes G, Shen T, Jensen R, Otterson G, Grever M, Au J, **Villalona-Calero M**. A Phase I Study of Non-Cytotoxic Suramin as a Modulator of Docetaxel and Gemcitabine in Patients with NSCLC. Cancer Chemotherapy and Pharmacology 2010 Nov; 66 (6):1019-29 PMID 20107799. PMID:PMC2919610
70. Yan F, Wu X, Crawford M, Duan D, Wilding E, Gao L, Nana-Sinkam SP, **Villalona-Calero M**, Baiocchi R, Otterson G. The Search for an Optimal DNA, RNA, and Protein Detection by *in situ* Hybridization, Immunohistochemistry, and Solution-Based Methods. Methods. 2010; 52(4):281-6. PMID: 20888418. PMID:PMC3375896
71. Bekaii-Saab T, Phelps M, Li X, Saji M, Goff L, Kauh J, O'Neil B, Balsom S, Balint C, Liersemann R, Vasko V, Marsh W, Doyle LA, Ellison G, Grever G, Ringel M, **Villalona Calero M**. A Multi-Institutional Phase II Study of Selumetinib (AZD6244, ARRY142886) in Patients with Metastatic Biliary Cancers. Journal of Clinical Oncology. 2011; 29 (17): 2357-2363 PMID: 21519026. PMID: PMC3107751
72. Blum K, Ruppert A, Woyach J, Jones J, Andritsos L, Flynn J, Rovin B, **Villalona-Calero M**, Ji J, Phelps M, Johnson A, Grever M, and Byrd J. Risk Factors for Tumor Lysis Syndrome (TLS) in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol. Leukemia. 2011 May 24. [Epub ahead of print] PMID:21606960. PMID:PMC3162125
73. Ramalingam S, Davies A, Longmate J, Edelman M, Lara P, Vokes E, **Villalona-Calero M**, Gitlitz B, Reckamp K, Salgia R, Wright J, Belani C, Gandara D. Bortezomib for Patients with Advanced Stage Bronchioloalveolar Carcinoma (BAC): A California Cancer Consortium Phase II Study (NCI # 7003). Journal of Thoracic Oncology. 2011 Oct;6(10):1741-5. PMID: 21716143. PMID:PMC3220078

74. Wu X, Wang L, Han Y, Regan N, Li P, **Villalona M**; Hu X, Briesewitz R, Pei D. Creating Diverse Target-Binding Surfaces on FKBP12: Synthesis and Evaluation of a Rapamycin Analogue Library. ACS Combinatorial Science. 2011 Sep 12;13(5):486-95. PMID: 21766878. PMCID:PMC3171579
75. Lam E, Goel S, Schaaf L, Cropp G, Hannah A, Zhou Y, McCracken B, Haley B, Mani S, **Villalona-Calero M**. Phase I Dose Escalation Study of KOS-1584, a Novel Epothilone, in Patients with Advanced Solid Tumors. Cancer Chemotherapy & Pharmacology. 2012 Feb;69(2):523-31. [PMID; 21874318]
76. Monk JP, Dupont J, **Villalona-Calero M**, Larkin J, Otterson G, Spriggs DS, Hannah AL, Cropp GF, Johnson RG, Hensley ML. A Phase 1 study of KOS-862 (epothilone D) Co-administered with Carboplatin (paraplatin) in Patients with Advanced Solid Tumors. Investigational New Drugs. 2012 (4):1676-83. [PMID: 21826439]
77. Jänne P, Wang X, Stinchcombe T, Crawford J, Socinski M, Gu L, Capelletti M, Edelman M, **Villalona-Calero M**, Kratzke R, Vokes E and Miller V. A randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: Cancer and Leukemia Group B trial 30406. Journal of Clinical Oncology, 30:2063-2069, 2012. PMCID: PMC3397694
78. Zhao W, Chen H, Otterson G, Leon M, Tang Y, Shilo K and **Villalona M**. Altered p16INK4 and RB1 Expressions Are Associated with Poor Prognosis in Patients with Non-Small Cell Lung Cancer. Journal of Oncology, 2012;2012:957437. PMCID: PMC3350860
79. Peck J, Wei L, Zalupski M, O'Neil B, **Villalona MA**, Bekaii-Saab T. HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib. Oncology, 2012;82(3):175-9.
80. Wu C, Fernandez S, Criswell T, Chidiac T, Guttridge D, **Villalona-Calero, MA**, Saab T. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas. 2013 Jul;42(5):813-8 PMCID:PMC3664263[Available on 2014/7/1]
81. Bertino E, Bekaii-Saab T, Fernandez S, Diasio R, Karim N, Otterson G, **Villalona-Calero M**. A Phase II Study of Modulated-Capecitabine and Docetaxel in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Lung Cancer 2013 79(1):27-32. PMCID:PMC3549571
82. Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn D, Shapiro C, Andreassen P, Otterson G, and **Villalona-Calero M**. Assessment of FANCD2 nuclear foci formation in paraffin embedded tumors: a potential patient enrichment strategy for treatment with DNA interstrand crosslink agents. Translational Research. 2013 Mar;161(3):156-64
83. Chu B, Karpenko M, Liu Z, Aimiuwu J, **Villalona-Calero MA**, Chan K, Grever M, Otterson GA. Phase I study of 5-aza-2'-deoxycytidine in combination with Valproic Acid in Non-Small Cell Lung Cancer. Cancer Chemotherapy & Pharmacology. 2013 71(1):115-21

84. Wang H, Chen P, Wang J, Santhanam R, Aimiwu J, Saradhi V, Liu Z, Schwind S, Mims A, Klisovic R, Walker A, Grever M, **Villalona-Calero MA**, Bloomfield C, Byrd J, Garzon, R, Blum W, Chan K, Marcucci G. In vivo Quantification of Active Decitabine-Triphosphate Metabolite: a Novel Pharmacanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia. The AAPS Journal. 2013 15(1):242-9. PMID:PMC3535094
85. Wu X, Upadhyaya P, **Villalona-Calero M**, Briesewitz R, Pei D. Inhibition of Ras-Effector Interaction by Cyclic Peptides. Medicinal Chemistry Communications, 2013, 4:378-382 PMID:23585920. PMID:PMC3621770
86. Haraldsdottir H, Li Q, **Villalona-Calero M**, Olencki T, Kendra K, Ing S. A case of sorafenib-induced thyroid storm. Journal of Clinical Oncology. 2013 Jun 1;31(16):e262-4. PMID:23610115
87. Heist R, Wang X, Hodgson L, Otterson G, Stinchcombe T, Ghandi L, **Villalona-Calero M**, Watson P, Vokes E, Socinski M, for the Alliance for Clinical Trials in Oncology. CALGB 30704 (Alliance): A Randomized Phase II Study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology 2014 Feb;9(2):214-21.
88. Shilo K, Wu X, Sharma S, Welliver M, Duan W, **Villalona-Calero M**, Fukuoka J, Sif S, Baiocchi R, Hitchcock C, Zhao W, Otterson G. Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagn Pathol. 2013 Dec 10;8(1):201. PMID: 24326178
89. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, **Villalona-Calero M**, Meyerson M, and Carbone D. Oncogenic *ARAF* mutation in a metastatic lung adenocarcinoma from a patient exhibiting dramatic sorafenib response. J Clin Investigation 2014 Apr 1;124(4):1582-6
90. Phelps M, Stinchcombe T, Blachly J, Zhao W, Schaaf L, Starrett S, Wei L, Poi M, Wang D, Papp A, Aimuwu J, Otterson G, Hicks W, Socinski M, **Villalona-Calero M**. EGFR-Tyrosine Kinase Inhibitor Therapy in African Americans with Advanced Non-Small Cell Lung Cancer: a Prospective Clinical, Pharmacogenetic, and Pharmacokinetic Study. Clinical Pharmacology & Therapeutics. Clinical Pharmacology and Therapeutics. 2014, 96(2):182-91
91. Chen W, Brodsky S, Zhao W, Otterson G, **Villalona-Calero M**, Satoskar A, Hasan A, Pelletier R, Ivanov I, Ross P, Nadasdy T, Shilo K. Y-Chromosome Status Identification Suggests a Recipient Origin of Post-Transplant Non-Small Cell Lung Carcinomas: Chromogenic in situ Hybridization Analysis Human Pathology. Human Pathology. 2014 45(5):1065-70.
92. Singh M, Leasure J, Chronowski C, Geier B, Li N, Bondra K, Duan W, Hensely L, **Villalona-Calero M**, Vergis A, Kurmasheva R, Shen C, Woods G, Sebastian N, Fabian D, Kaplon R, Hammond S, Houghton P, Palichamy K, Chakravarti A. FANCD2 is a Potential Therapeutic Target and Biomarker in Pediatric Rhabdomyosarcoma. Clinical Cancer Research, 2014 20(14):3884-95.
93. Yilmaz A, Mohamed N, Patterson K, Tang Y, Shilo K, **Villalona-Calero M**, Davis M, Zhou X, Frankel W, Otterson G, Gewirtz A, and Zhao W. Clinical and metabolic details in non-small cell lung carcinoma and colorectal cancer patients with and without *KRAS* mutations. International Journal of Environmental Research and Public Health, 2014 11:8645-8660

94. Yilmaz A, Mohamed N, Patterson K, Tang Y, Shilo K, **Villalona-Calero M**, Davis M, Zhou X, Frankel W, Otterson G, Beall H, and Zhao W. Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations. International Journal of Environmental Research and Public Health 2014;11(9):9491-502
95. Kendra K, Plummer R, Salgia R, O'Brien M, Paul E, Suttle A, Compton N, Xu C, Ottesen L, **Villalona-Calero M**. A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics 2015;14(2):461-9
96. Zhao W, Damodaran S, **Villalona-Calero M**. From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience. Lung Cancer Management. 2014 Aug 1;4(3):315-324.
97. Duan W, Gao L, Aguila B, Kalvala A, Otterson GA, **Villalona-Calero MA**. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front Oncol. 2014 Dec 19;4:368
98. Kalvala A, Gao L, Aguila B, Reese T, Otterson G, **Villalona-Calero M**, Wenrui Duan. Overexpression of Rad51C splice variants in colorectal tumors. Oncotarget 2015;6(11):8777-87.
99. Kummar S, Oza A, Fleming G, Sullivan D, Gandara D, Erlichman C, **Villalona-Calero M**, Morgan R, Szabo P, Youn A, Chen A, Ji J, Allen D, Lih C, Mehaffey M, Walsh W, McGregor III P, Steinberg S, Williams P, Kinders R, Conley B, Simon R, Doroshow J. Randomized trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with advanced, recurrent ovarian, primary peritoneal, or fallopian tube cancers. Clinical Cancer Research 2015;21(7):1574-82
100. Ahn D, Li J, Wei L, Yereb M, Doyle A, Marshall J, Timmers C, Shaaf L, Phelps M, **Villalona-Calero M**, Bekaii-Saab T. Akt inhibition with single agent MK-2206 may not be effective in Biliary Cancers: Results of an Abbreviated Phase II Trial. Scientific Reports 2015, 5:12122
101. Bertino E, Williams T, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Cantrell S, Rahmani M, Symmes C, Phillips G, **Villalona-Calero M**, Otterson G. Stromal Caveolin-1 is Associated with Response and Survival in a Phase II trial of nab-Paclitaxel plus Carboplatin for Advanced NSCLC Patients. Clin Lung Cancer; 2015 16(6):466-474
102. Mikhail S, Lustberg M, Rupert A, Mortazavi A, Monk P, Kleiber B, **Villalona-Calero M*** and Bekaii-Saab T*. Biomodulation of Capecitabine by Paclitaxel and Carboplatin in Advanced Solid Tumors and Adenocarcinoma of Unknown Primary. *Co-senior authors. Cancer Chemotherapy & Pharmacology. 2015 Nov;76(5):1005-12
103. **Villalona-Calero M**, Lam E, Otterson G, Zhao W, Timmons M, Subramaniam D, Hade E, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp M. Oncolytic Reovirus in Combination with Chemotherapy in Metastatic or Recurrent Non-Small Cell Lung Cancer Patients with Kras Activated Tumors. Cancer 2015 Dec 28. [Epub ahead of print]
104. Farren M, Mace T, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan A, **Villalona-Calero M**, Bekaii-Saab T, Lesinski G. Systemic immune activity predicts overall

survival in treatment naïve patients with metastatic pancreatic cancer. Clinical Cancer Research 2015 Dec 30. [Epub ahead of print].

105. **Villalona-Calero M**, Duan W, Zhao W, Shilo K, Schaaf L, Thurmond J, Westman J, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors with Functional Deficiency in Homologous Recombination Repair. Journal of The National Cancer Institute 2016 Feb 4;108(7).

Original Reports Submitted or in Preparation:

1. Abuzakhm S, Fruth B, Qin R, **Villalona-Calero M**, Erlichman C, Shah M. Multicenter Phase II Study of Bevacizumab and Temozolomide in patients with Advanced Neuroendocrine tumors. Submitted.
2. Noonan A, Huang Y, Chen J, Tahiri S, Ahn D, Lesinski G, Mikhail S, Ciombor K, Pant S, Aparo S, Sexton J, Marshall J, Mace T, Farren M, Wu C, El-Rayes B, Timmers C, Geyer S, Zwiebel J, **Villalona-Calero M***, T. Bekaii-Saab*. A Multi-Institutional Randomized Phase II Trial of the Oncolytic Virus Pelareorep in the First Line Treatment of Metastatic Adenocarcinoma of the Pancreas. * Co-senior authors. Submitted.
3. Adelson K, Ramaswamy B, Sparano J, Christos P, Wright J, Raptis G, Han G, **Villalona-Calero M**, Ma C, Hershman D, Baar J, Klein P, Cigler T, Budd T, Novik Y, Tan A, Tannenbaum S, Goel A, Levine E, Shapiro C, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.. A Randomized Phase II Trial of Fulvestrant Alone or in Combination with Bortezomib in Hormone Receptor-Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitors: A New York Cancer Consortium Trial. Submitted.
4. Kalvala A, Gao L; Aguila B; Dotts K; Rahman M, Nana-Sinkam S P, Zhou X, Otterson G, **Villalona Calero M**, Duan W, Ph.D. Rad51C-ATXN7 fusion gene expression in colorectal tumors. Molecular Cancer. Accepted Pending Revisions.
5. Noonan A, Chen J, Huang Y, Geyer S, Jin M, Frankel W, Timmers C, Zwiebel J, **Villalona-Calero M**, Bekaii-Saab T. CEACAM6 is a candidate biomarker for Reolysin® (pelareorep) resistance in pancreatic adenocarcinoma. Submitted.

Letters to the Editor/Editorials:

1. Vaickus Louis, **Villalona-Calero Miguel A.**, Caligiuri Therese, Acute Progranulocytic Leukemia (APL): Possible In Vivo Differentiation by Granulocyte-Colony Stimulating Factor (G-CSF). Leukemia, 7(10): 1680-81, 1993
2. **Villalona-Calero Miguel A.**, Pretraining for International Medical Graduates. Annals of Internal Medicine, 118(5): 397-398, 1993
3. **Villalona-Calero Miguel A.**, Secondary Acute Myelogenous Leukemia in Children with Latin-American Ancestry. Journal of Clinical Oncology, 11(11):2286, 1993
4. Weber F, Fukino K, **Villalona-Calero M**, Eng C. Limitations of SSCP as a high throughput method for the detection of *EGFR* mutations in the clinical setting. Journal of Clinical Oncology, 23 (24): 5847-5848, 2005

5. Shah M, **Villalona-Calero M**, Marcucci G, Byrd J, and Grever M. Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Cancers. Clinical Cancer Research 13(3):1068, 2007
6. Bertino E, **Villalona-Calero M**, Ross P, Grever M, Otterson G. Preoperative Bevacizumab in Combination with Paclitaxel and Carboplatin in Surgically Resectable Non Small Cell Lung Cancer. The Annals of Thoracic Surgery 91(2):640, 2011

Invited Editor Reviewed Articles:

1. Rivas-Perez H, Villalona, M. Rehabilitacion Pulmonar para Pacientes con Cancer del Pulmon. Neumos, 23 (1), 2014: 22-25
2. Grenade C, Phelps M, **Villalona-Calero, M**. Race and Ethnicity in Cancer Therapy. What Have We learned? Clinical Pharmacology & Therapeutics. 2014 Apr;95(4):403-12
3. Chao B, Briesewitz R. **Villalona-Calero MA**. RET fusion genes in non-small-cell lung cancer. Understanding the pathway. Journal of Clinical Oncology, 30(35):4439-41
4. Kindwall-Keller T, **Villalona-Calero M**. Elinafide, Current status of an active naphtalimide. Expertos Invitados. Journal of the Iberoamerican Society of Scientific Information (SIIC Salud). April 7, 2003
5. Dizon D, Krilov L, Cohen E, Ganghadar T, Ganz P, Hensing T, Hunger S, Krishnamurthi S, Lassman A, Marham MJ, Mayer E, Neuss M, Kumar S, Richardson L, Schilsky R, Schwartz G, Spriggs D, **Villalona-Calero M**, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report On Progress Against Cancer From The American Society Of Clinical Oncology. Journal of Clinical Oncology. J Clin Oncol. 2016 Feb 4. pii: JCO658427. [Epub ahead of print]

Other Reviews:

6. Eckardt J, Eckhardt G, **Villalona-Calero M**, Drengler R, Von Hoff D. New Anticancer agents in clinical development. Oncology, 9(12): 1321-1328, 1995
7. Eckardt J, Eckhardt G, **Villalona-Calero M**, Drengler R, Von Hoff D. New Anticancer agents in clinical development. Oncology, 9(11): 1191-1199, 1995.
8. **Villalona-Calero M**. Nuevas Drogas. Oncologia Clinica, 2(3): 54-55, 1997.
9. Rothenberg M, Kuhn J, Schaaf L, Drengler R, Eckhardt SG, **Villalona-Calero M**, Hammond L, Miller L, Rowinsky E, Von Hoff D. Alternative Dosing Schedules for Irinotecan. Oncology, 12 (8): 68-71, 1998.
10. **Villalona-Calero, M**. Capecitabine/taxane combinations: current status. Cancer Conference Highlights, 3(6): 5-7, 1999
11. **Villalona-Calero, M**. Reflexiones con respecto al cancer del pulmon y su tratamiento. Cancer Team: Salud y Medicina para la vida. 1(1) April 2001 <http://cancerteam.tripod.com/ctmenl.html>.
12. Maher J, **Villalona-Calero M**. Taxanes and Capecitabine in Combination: Rationale and Results of Clinical Trials. Clinical Breast Cancer. 2: 287-293, 2002

13. **Villalona-Calero M.** Docetaxel and Capecitabine in Combination: Synergistic Interactions and Scheduling Issues. Advances in Breast Cancer 4, No 2: 6-8, 2002
14. Xu Yiqing, **Villalona-Calero M.** Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Annals of Oncology. 13(12):1841-51, 2002
15. Mock V, Atkinson A, Barsevick A, Blackwell S, Cella D, Cianfrocca M, Cimprich B, Cleeland C, Dean G, Eisenberger M, Escalante C, Garst J, Hinds P, Jackson V, Jacobsen P, Kaldor P, O'Connor T, Oleksowicz L, Piper B, Rugo H, Sabbatini P, Stahl C, Stewart F, **Villalona M**, Von Roenn J, Wagner L, Wexler L. Cancer-Related Fatigue. Clinical Practice Guidelines in Oncology. Journal of The National Comprehensive Cancer Network 1, No 3: 308-331, 2003
16. Bekaii-Saab T, **Villalona-Calero M.** Preclinical experience with docetaxel in gastrointestinal cancers. Seminars of Oncology. 32(2 Suppl 4):S3-9, 2005.
17. **Villalona-Calero M.** Predictive factors of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. The American Journal of Hematology/Oncology Vol 6 No7: 1-3, 2007
18. Pant S, **Villalona-Calero MA.** Lung Cancer Highlights of ASCO 2007. Lung Cancer Frontiers. 31: 5-7, 2007.
19. Leon, Marino E., **Villalona-Calero, Miguel.** Evaluacion Patologica Del Carcinoma De Pulmon de Celulas No Pequenas (No-microcitico): Histologia, e Immunohistoquimica. Neumos. Vol. 21 No.1, Jan. – June 2010.

Book Chapters

1. Britten C, Hammond L, Hidalgo M, Rothenberg M, Sharma A, Sharma S, Siu L, **Villalona-Calero M**, Weiss G. New Anticancer Agents. In Cancer Chemotherapy and biological response modifiers. 18th Annual, 1999. Pinedo HM, Longo DL, and Chabner BA eds. Elsevier Science Publishers, B.V., Amsterdam.
2. **Villalona-Calero M.** Anti Cytokine Treatment. Chapter 23. In Cytokines in the Genesis and Treatment of Cancer. M.A. Caligiuri, M.T. Lotze & F. R. Balkwill eds. Humana Press., 2006
3. **Villalona-Calero M**, Schaaf L, Turowsky R. Antimicrotubule Agents. In Cancer Drug discovery and Development. Checkpoint Responses and Cancer Therapy" B. W. Dai, ed. Humana Press, Inc, Totowa, NJ 2008

Abstracts

1. **Villalona M**, Alvarez F, Bido R, Gautier T, Imperato-McGinley J. Incomplete Insensitivity to Androgens, First Cases Studied in The Dominican Republic. Fourth Student Congress on Scientific Research. San Juan, Puerto Rico, Jan. 1986.

2. **Villalona-Calero Miguel A.**, Stewart, C., Barcos, M., Baiocchi, R., Caligiuri, M., Foon, K.A., Phenotypic Characteristics of "Prolymphocytoid" Transformed (CLL/PLL) Chronic Lymphocytic Leukemia (CLL) Cells Proceedings of ASCO. Vol. 10, March 1991.
3. **Villalona-Calero MA.**, Budnick R., Walsh D., Levine EG., Stewart C., Penetrante R., Tsangaris T., Raghavan D., Minimum 6 years Follow-up of 133 Patients aged > 70 years Treated for Breast Cancer. Proceedings of ASCO. Vol 13 (154), 1993.
4. **Villalona-Calero M.**, Degen, D., Barlozzari T., Von Hoff D., LU103793: Evaluation by human tumor clonogenic assay of a novel dolastatin. Proceedings of AACR, 1995.
5. Rothenberg ML, Rinaldi DA, Smith LS, Schaaf LJ, Hodges S, Thurman AM, Ichhpurani NK, Eckhardt SG, Rodriguez GI, **Villalona M**, Drengler R, Von Hoff DD. Phase I and pharmacokinetic trial of Irinotecan (CPT-11) administered on an every-other-week schedule. Proceedings 6th Conference on DNA Topoisomerases in Therapy 82: 1995.
6. **Villalona-Calero M**, Jackimowicz K, Razvillas B, Rinaldi D, Eckhardt G, Aylesworth C, Fischkoff S, Von Hoff D. LU103793: A phase I study of a novel dolastatin. Proceedings of the 9th NCI-EORTC symposium on new drugs in cancer therapy, 1996.
7. P. Reidenberg, **M. Villalona**, G. Eckhardt, G. Rodriguez, H. Burris, D. Von Hoff, P. Statkevich, V. Batra, M. Dugan, J. Eckardt. Phase I and pharmacokinetic study of Temozolomide (Temodal) in advanced cancer patients stratified by extent of prior therapy. Proceedings of the 9th NCI-EORTC symposium on new drugs in cancer therapy, 1996.
8. **Villalona-Calero M**, Degen D, Bousquet P, Von Hoff D. LU 79553: evaluation by human tumor clonogenic assay of a novel naphthalamide. Proceedings of AACR, Vol 37 1996:398.
9. **Villalona-Calero M**, Hadovsky G, Bazan C, Lancanter J, Hander T, Goldblum R, Hammond L, Bari A, Drengler R, Von Hoff D, Eckardt J. Human corticotropin-releasing factor (hCRF): A new approach to peritumoral brain edema. Proceedings of AACR, Vol 37 1996:212.
10. Kolesar J, **Villalona-Calero M**, Eckhardt G, Rodriguez G, Rinaldi D, Von Hoff D, Kuhn, J. Detection of a point mutation and the alternative splice NQO1 gene in patients with colon cancer. Proceedings of ASCO 15: 1996.
11. Rothenberg M., Rinaldi D., Smith L., Schaaf S., Hodges S., Thurman A, Ichhpurani N., Eckhardt G., Rodriguez G., **Villalona M.**, Drengler R., Dietz A., Murphy T., Burris H., Von Hoff D. Every other week Irinotecan (CPT-11): Results of a phase I and pharmacokinetic (PK) study. Proceedings of ASCO 15: 1996.
12. **Villalona-Calero, M.**, Moczygemba J., Atkins I., Thurman, A., Rodriguez G., McCune, D., Drengler, R. Griffin, T. Osterwalder, B., Von Hoff, D. Paclitaxel-Capecitabine: Results of a dual escalation phase I and pharmacokinetic (PK) study. *Annals of Oncology*. Vol 7 (suppl 5):127, 1996.
13. Allen, S., **Villalona-Calero, M.**, Jakimowicz, K., Fram, R., O'Mara, V., Kolitz, J., Gallagher, M., Van Echo, D., Fischkoff, S., and O'Dwyer, P. Phase I study to determine the safety of LU103793 as a 5-minute IV infusion, every other day X 3 every 3 weeks, in patients with malignant solid tumors. Proceedings of AACR 38, 1997:1498.
14. Rowinsky E, Smith L, Chaturvedi P, Wang Y, Campbell E, Hatch S, Harding M, Aylesworth C, Eckhardt G, **Villalona M**, Drengler R, Kraynak M, Von Hoff D. Pharmacokinetic (PK) and

- toxicologic interactions between the multidrug resistance (MDR) reversal agent VX-710 and paclitaxel (P) in cancer patients. Proceedings of ASCO, 1997.
15. **Villalona-Calero M**, Von Hoff D, Eckhardt G, Aylesworth C, Hammond L, Drengler R, Razvillas B, Kraynak M, Jackimowicz K, Fram R, Velagapudi R, Rowinsky E. Phase I and pharmacokinetic (PK) study of LU103793, a water soluble analog of dolastatin-15 on a daily x 5 schedule. Proceedings of ASCO, 1997.
 16. Rodriguez GI, De Moor C, White L, Hammond L, Thurman A, **Villalona M**, Kraynak M, Burris HA, Stolz M, Belker M, Offord S, Von Hoff DD. A phase I evaluation of MDL 101,731 administered every 21 days (d), utilizing the modified continual reassessment method for dose escalation. Proceedings of ASCO, 1997.
 17. Rowinsky E, Smith L, Chaturvedy P, Wang YMC, Campbell E, Hatch S, Harding M, Aylesworth C, Eckhardt G, **Villalona M**, Drengler R, Kraynak M, and Von Hoff D. Pharmacokinetic (PK) and toxicologic interactions between the multidrug resistance (MDR) reversal agent VX-710 and paclitaxel (P) in cancer patients. Proceedings of ASCO, 1997.
 18. Hammond L, Eckardt J, Kuhn J, Rizzo J, Johnson T, **Villalona M**, Smith L, Drengler R, Rowinsky E, Coltman CA, Von Hoff D. Phase I and pharmacokinetic (PK) trial of sequences of BCNU and temozolomide (TMZ) in patients with solid neoplasms. Proceedings of ASCO, 1997.
 19. Rothenberg M, Kuhn J, Burris H, Drengler R, Schaaf L, Petit R, Eckhardt S, **Villalona-Calero M**, Weiss G, Hammond L, Hodges S, Miller L, Rowinsky E, Von Hoff. Irinotecan (CPT-11): Learning how to run with scissors. Proceedings of the 8th conference on DNA topoisomerases in therapy, 1997.
 20. Eckhardt SG, **Villalona M**, Hammond L, Moczygemba J, Kraynak M, de Moor C, Von Hoff D, Rowinsky E. A Phase I study of AN-9 (pivaloyloxymethylbutyrate, PivanexTM), a lipophilic butyric acid analog, in patients with advanced solid tumors. Proceedings of AACR, 1998.
 21. Petit T, **Villalona-Calero M**, Kuhn J, Kraynak M, Smith L, Aylesworth C, Drengler R, Simmons C, Cobb P, Santabarbara P, Von Hoff D, Rowinsky E. Phase I and Pharmacokinetic Study of Crisnatol Mesylate on a Prolonged Infusion Schedule in Cancer Patients (pts). Proceedings of ASCO, 1998.
 22. Hammond L, **Villalona-Calero M**, Eckhardt SG, Drengler R, Aylesworth C, Johnson T, Hidalgo M, Rodriguez G, Diab S, Monroe P, Thornton D, Von Hoff D, and Rowinsky E. A Phase I and Pharmacokinetic (PK) Study of the Multitargeted antifol (MTA) LY231514 with Folic Acid. Proceedings of ASCO, 1998.
 23. **Villalona-Calero M**, Eder JP, Toppmeyer D, Allen LF, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, O'Connor L, Fram R, Kufe D, Von Hoff D, and Rowinsky E. Phase I and Pharmacokinetic (PK) study of LU79553, A Novel Bis-Naphthalamide on a Daily x 5 Schedule. Proceedings of ASCO, 1998.
 24. Khoury P, **Villalona-Calero M**, Blum J, Diab S, Elledge R, Kraynak M, Moczygemba J, Kromelis P, Morales I, Brown C, Griffin T, Von Hoff D, Rowinsky E. Phase I study of Capecitabine in Combination with Paclitaxel in Patients with Previously treated Metastatic Breast Cancer. Proceedings of ASCO, 1998.

25. Rodriguez G, **Villalona-Calero M**, Schwartz G, Thurman A, Drengler R, Kraynak A, Johnston A, Clendenin N, Von Hoff DD, Rowinsky E. A Phase I and Pharmacokinetic (PK) Study of Thymitaq (AG337) in Combination with Cisplatin (CDDP) in Patients (PTS) with Advanced Solid Tumors. Proceedings of ASCO, 1998.
26. Hidalgo M, **Villalona-Calero M**, Drengler R, Hammond L, Diab S, Campbell E, Louie A., O'Neil J, Von Hoff D, Rowinsky E. A phase I and Pharmacokinetic (PK) Study of the oral Uridine Prodrug PN401 as a Rescue Agent for Escalating Doses of 5-Fluorouracil (5FU) in Patients with Advanced Cancer. Proceedings of ASCO, 1998.
27. Jimeno J, **Villalona-Calero M**, Eckhardt G, Weiss G, Campbell E, Hidalgo M, Siu L, Britten C, Kraynak M, Beijnen J, Von Hoff D, Rowinsky E. Phase I And Pharmacokinetic (PK) Study of ET-743, a Novel Minor Groove Binder of Marine Origin on a daily x 5 Schedule. Proceedings of ASCO, 1998.
28. Diab S, Baker S D, Hammond L, **Villalona M**, Eckhardt SG, Tinu C, Weiss G, Kraynak M, Aylesworth C, Smith L, Rodriguez G, Drengler R, Patil R, Siu L, Rothenberg M, Smetzer L, Nyhart E, Storniolo A M, Von Hoff D, and Rowinsky E. Phase I and pharmacokinetic (PK) study of the iarylsulfonylurea LY295501 administered as a single oral dose weekly for 3 weeks every 4 weeks. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998 (abstr 440)
29. Eckhardt S G, **Villalona M A**, Kraynak M, Moczygemba J, Von Hoff DD, Rowinsky EK. A phase I study of AN-9 (pivaloyloxymethylbutyrate, PivanexTM), a lipophilic butyric acid analog, in patients with advanced solid tumors. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998 (abstr 318)
30. Hammond L, Baker SD, **Villalona-Calero M**, Eckhardt SG, Drengler R, Aylesworth C, Johnson T, Hidalgo M, Rodriguez G, Diab S, Monroe P, Thornton D, Johnson R, Von Hoff D, and Rowinsky E. A phase I and pharmacokinetic (PK) study of the multitargeted antifol (MTA) LY231514 with folic acid (FA). Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998 (abstr 612).
31. **Villalona-Calero M**, Eckhardt SG, Weiss G, Campbell E, Hidalgo M, Kraynak M, Beijnen J, Jimeno J, Von Hoff D, Rowinsky E. A Phase I And Pharmacokinetic Study of ET-743, a Novel DNA Minor Groove Binder of Marine Origin Administered as a 1-hour infusion daily x 5 Days. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998 (abstr 453).
32. **Villalona-Calero M**, Blum J, Diab S, Elledge R, Khoury P, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Von Hoff D, Rowinsky E. Phase I study of Capecitabine in Combination with Paclitaxel in Patients with Previously treated Metastatic Breast Cancer. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998. (abstr 370)
33. Hidalgo M, **Villalona-Calero M**, C Britten, L. Siu, Drengler R, Hammond L, Diab S, Campbell E, Louie A., O'Neil J, Von Hoff D, Rowinsky E. A phase I and Pharmacokinetic (PK) Study of PN401 as a Rescue Agent for Escalating Doses of 5-Fluorouracil (5-FU) in Patients (PTS) with Cancer. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998 (abstr 625).
34. Hammond L, Eckardt J, Kuhn J, Rizzo J, Johnson T, **Villalona-Calero M**, Smith L, Drengler R, Campbell L, Von Hoff D, Rowinsky E. Phase I and pharmacokinetic (PK) trial of sequences of BCNU and temozolomide (TMZ) in patients with solid neoplasms. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998. (abstr 441)

35. **Villalona-Calero M**, Eder J, Toppmeyer D, Allen L, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, O'Connor L, Fram R, Kufe D, Von Hoff D, and Rowinsky E. Phase I and Pharmacokinetic (PK) study of LU79553, A Novel Bis-Naphthalamide on a Daily x 5 Schedule. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998. (abstr 249)
36. Rothenberg ML, Kuhn JG, Schaaf LJ, Eckhardt SG, **Villalona-Calero MA**, Petit RG, Miller LL, Elfring GL, Murphy TC, Von Hoff DD. Phase I and pharmacokinetic study of intravenous irinotecan (CPT-11) administered once every 2 weeks +/- G-CSF. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998 (abstr 240).
37. Gallagher M, Allen S, Stevenson J, Hiller K, O'Mara V, Velagapudi R, Mitchell E, **Villalona M**, Van Echo D, Jakimowicz K, Allen L, Fischkoff S, O'Dwyer P. Phase I trial of the dolastatin-15 analogue LU-103793 (Cemadotin) every other day for three doses. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998. (abstr 386)
38. Rosing H, Hillebrand M, Jimeno J, Gomez A, Floriano P, Faircloth G, Henrar R, Vermorken J, Cvitkovic E, **Villalona M**, Bult A, Beijnen J. Determination of ecteinascidin 743 in human plasma; comparison of conventional LC/UV to miniaturized LC/electrospray ionization tandem mass spectrometry. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998. (abstr 454)
39. Hillebrand M, Jimeno J, Bowman A, Cvitkovic E, Hoekman K, Hoppener F, Twelves C, **Villalona M**, Rosing H, Beijnen J. Pharmacokinetics of ecteinascidin-743 (ET-743) in three phase I studies. Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, 1998. (abstr 455)
40. Hidalgo M, **Villalona-Calero M**, Eckhardt SG, Weiss G, Campbell E, Kraynak M, Beijnen J, Jimeno J, Von Hoff D, Rowinsky E. A Phase I and pharmacokinetic (PK) study of ET-743, a novel minor groove binder of marine origin administered on a daily x 5 schedule. *Annals of Oncology* (Suppl 4) vol 9: 127, 1998
41. Hammond L, **Villalona-Calero M**, Eckhardt SG, Siu L, Hidalgo M, Thornton D, Walling J, Baker S, Coltman C, Von Hoff D, Rowinsky E. A Phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid (FA). *Annals of Oncology* (Suppl 4) vol 9: 129, 1998
42. **Villalona-Calero M**. Eckhardt SG, Hammond L, Campbell E, Smith L, Hidalgo M, Britten C, Beijnen J, Guzman C, Jimeno J, Von Hoff D, Rowinsky E. Final Results of a Phase I and Pharmacokinetic (PK) Study of The Marine Minor Groove Binder ET-743 on a Daily X 5 Schedule. Proceedings of ASCO, 1999 (abstr 691)
43. **Villalona-Calero M**. Capecitabine and Paclitaxel: A synergistic combination? *Cancer Investigation* (Suppl 1) vol 17: 37, 1999
44. Beijnen J, Rosing H, Cvitkovic, Hillebrand M, Twelves C, **Villalona M**, Jimeno J. Pharmacokinetics (PK) and Pharmacodynamics (PD) of ET-743 (Ecteinascidin-743) in Phase I trials. Proceedings of ASCO, 1999 (abstr 629)
45. Johnson T, Hammond L, Johnson R, Drengler R, Eckhardt SG, Neumanitis J, **Villalona M**, Williams T, Diab S, Walling J, Simmons C, Von Hoff D, and Rowinsky E. Phase I and Pharmacokinetic Study (PK) of the Multitargeted Antifol LY231514 (MTA) in Combination with Irinotecan (CPT-11). Proceedings of ASCO, 1999 (abst 659)

46. Tinu C, Diab SG, Smith L, Hammond L, Baker S, **Villalona-Calero M**, Eckhardt SG, Weiss G, Smetzer L, Thornton D, Rowinsky E, Von Hoff D. Phase I and Pharmacokinetic (PK) Study of the Diarylsulfonylurea LY295501 Administered Orally Weekly for 3 Weeks Every 4 Weeks. Proceedings of ASCO, 1999 (abstr 687)
47. Tan W, Tin-U C, Zellars R, Herman T, **Villalona-Calero M**, Valley A, Kalidas M, Ochoa L, Drengler R, Khoury P, Alder L, Barns J, Hardy J, Bready B, Weiss G, Otto R, Rowinsky E, Diab SG. Phase I Study of Weekly paclitaxel in Combination with Daily Cisplatin and Radiation in Locally Advanced Non-Small Cell Lung Carcinoma (NSCL), and Esophageal Carcinoma. Proceedings of ASCO, 1999 (abstr 1582)
48. Kolesar J, Hillman L, Drengler R, Hammond L, Diab S, Felton S, Monroe P, Schaaf L, Von Hoff D, Kuhn J, Rowinsky E, **Villalona-Calero M**. Evaluation of NQO1 Gene expression and Point Mutations in Patients receiving Mitomycin-C and Irinotecan. Proceedings of the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Molecular Targets and Cancer Therapeutics, 1999 (abstr 574)
49. Gomez J, Lopez Lazaro , Guzman C, Gonzales A, Misset J, Twelves C, Bowman A, Hoekman K, **Villalona M**, Ryan D, Paz-Ares L, Jimeno J. Identification of Biochemical Parameters That Predict the Onset of Severe Toxicities in patients Treated with ET-743. Proceedings of ASCO, 2000 (abstr 727)
50. **Villalona-Calero MA**, Shapiro C, Otterson GA, Hauger M, Kraut E, Clinton S, Shah M, Stanek M, Monk P. Phase I Study of Weekly Docetaxel in Combination with Capecitabine in Patients with Solid Malignancies. San Antonio Breast Cancer Symposium 2000 (abstr 537)
51. **Villalona-Calero MA**, Kuhn J, Drengler R, Schaaf L, Otterson G, Shapiro C, Thurman A, Diab S, Hammond L, Rowinsky E, Felton S, Hauger M, Monroe P, Kolesar J. Phase I and Biological Study of Mitomycin-C (MMC) as a modulator of Irinotecan's (CPT-11) activity in patients with solid malignancies. 12th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 2000 (abstr 544)
52. Kolesar J, Olsen E, Drengler R, Felton S, Schaaf L, Von Hoff D, Kuhn J, **Villalona-Calero, M**. Evaluation of Topoisomerase I and NQO1 Gene Expression and NQO1 Point Mutation in Patients Receiving Mitomycin-C and Irinotecan. 12th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 2000 (abstr 232)
53. Leighl N, Warr D, **Villalona-Calero M**, Eckhardt SG, Herbst R, Hirte H, Pentz R, Rothenberg M, Sharma S, Stewart D, Siu L. North American survey of Phase I trial informed consent documents: what information do Phase I patients take home? 12th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 2000 (abstr 547)
54. Mauer A, Otterson G, Rudin C, **Villalona M**, Ansari R, Szeto L, and Vokes E. Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC). 12th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 2000 (abstr 549)
55. Duan W, Ding H, Subler M, Windle J, Otterson G, **Villalona-Calero M**. Lung specific expression of mutant p53 (273H) in mice. AACR, 2001 (abstr 1185)

56. **Villalona-Calero M**, Kuhn J, Drengler R, Schaaf L, Otterson G, Shapiro C, Thurman A, Diab S, Hammond L, Von Hoff D, Felton S, Hauger M, Monroe P, Rowinsky E, Kolesar J. Pharmacologically-based Phase I Study of Mitomycin C (MMC) as a Modulator of Irinotecan (CPT-11) Antitumor Activity. ASCO, 2001 (abstr 400)
57. Venook A, Klein C, Kastrissios H, Leichman C, Hollis D, Hohl R, **Villalona M**, Aylesworth C, Marshall J, Budman D, Rosner G, Ratain M. Phase I study of irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy. ASCO, 2001 (abstr 293)
58. O'Neil J, Marshall J, Doroshow J, **Villalona-Calero M**. Development and validation of a limited sampling strategy for estimating high-dose 5-fluorouracil (5FU) exposure following a 30-minute infusion. ASCO, 2001 (abstr 2074)
59. Hoffman PC, Mauer AM, Otterson GA, Rudin CM, **Villalona MA**, Golomb HM, Wade JL, Lanzotti VJ, Ansari RH, Szeto L, and Vokes EE. Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC). ASCO, 2001 (abstr 2852)
60. Chen D, Song S, Yeh T, Au J, **Villalona-Calero M**, Otterson G, Kanter S, Wientjes. Phase I pharmacokinetics of suramin in combination with paclitaxel and carboplatin in non small cell lung cancer patients. American Association Of Pharmaceutical Sciences Meeting, 2001
61. Song S, Chen D, Yeh T, Au J, **Villalona-Calero M**, Otterson G, Kanter S, Wientjes M. Prediction of suramin dosage in combination with paclitaxel and carboplatin in non small cell lung cancer in Phase II trial based on population pharmacokinetic analysis. American Association of Pharmaceutical Sciences Meeting, 2001
62. **Villalona-Calero M**, Otterson G, Kanter S, Young D, Fischer B, Traiko M, Chen D, Brooks R, Saeheum S, Zhang Y, Yeh TK, Chan K, Grever M, Wientjes G, Au J. A Phase I, pharmacokinetic (PK), and biological study of FGF inhibition modulating paclitaxel/carboplatin (P/C) chemotherapy in Non-Small Cell Lung cancer (NSCLC) patients (PTS). AACR-NCI-EORTC, Molecular Targets and Cancer Therapeutics, 2001 (abstr 77).
63. **Villalona-Calero M**, Figueroa J, Nadella P, Otterson G, Snider P, Browning K, D'Amato N, Geary R, Grundy J, Holmlund J. Phase I and Pharmacokinetic (PK) study of the protein kinase alpha (PKC- α) inhibitor ISIS-3521 in combination with cisplatin and gemcitabine in patients with solid malignancies. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, 2001 (abstr 763).
64. Ding H, Duan W, Zhu W, Ju R, Subler M, Otterson G, **Villalona-Calero, M**. Mechanisms of regulation of CHK2 expression after exposure to the topoisomerase II inhibitor genistein. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, 2001 (abstr 708).
65. P. Ritch, R. Belt, S. George, M. Valdivieso, J. Figueroa, S. McCachren, M. Modiano, G.L. Miller, J. Leonardo, A. Dorr, J.W. Oliver, J. Holmlund, G.A. Otterson, **M. Villalona-Calero**. Phase I/II Trial of ISIS 3521/LY900003/LY900003 Antisense Inhibitor of PKC-Alpha with Cisplatin and Gemcitabine in Advanced Non-Small Cell Lung Cancer (NSCLC). ASCO 2002 (abstr 1233).
66. **Villalona-Calero M**, Otterson G, Kanter S, Young D, Murgu A, Fischer B, Brooks R, Straiko M, Chen D, Song S, Zhang Y, Chan K, Grever M, Wientjes G, Au J. A novel Strategy to decrease taxane resistance in Non-Small-Cell Lung cancer patients. ASCO 2002 (abstr 1221)

67. Otterson G, Browning K, Wewers M, **Villalona-Calero M**, Ross P. Smoking characteristics of lung cancer patients and their family members. ASCO 2002 (abstr 2832)
68. Monk P, Waite R, Hauger M, Otterson G, Rhoades C, Caligiuri M, **Villalona-Calero M**. Tumor Necrosis Alpha (TNF) Blockade as an Adjunct to Maintain Chemotherapy Dosing. ASCO 2002 (abstr 45)
69. Kolesar J, Miller J, Duan W, Drengler R, Felton S, Schaaf L, Von Hoff D, Kuhn J, **Villalona-Calero M**. TI Induction in PBMC Predicts Response to MMC/CPT-11. ASCO 2002 (abstr 456)
70. Hoffman P, Winegarden J, Mauer A, Rudin C, **Villalona M**, Golomb H, Szeto L, Vokes E, Wade J, Otterson G. Phase II study of oxaliplatin (OX) and paclitaxel (PA) in advanced non-small cell lung cancer (NSCLC). ASCO 2002 (abstr 1321)
71. Zhu W, Dai Z, Srinivasam K, Ding H, Duan W, **Villalona M**, Plass C, Otterson G. Methylated Sp1 binding sites are responsible for p21 silencing. Proc AACR 2002, abstr 5527, 1115.
72. Chen D, Yeh T, Song S, Au JL, **Villalona-Calero M**, Otterson S, Kanter S, Chan K, Weintjes MG. Pharmacokinetics of low dose suramin in combination with paclitaxel and carboplatin in non-small cell lung cancer patients. Proc AACR 2002, abstr 2738, 551
73. Ding H, Duan W, Zhu W, Otterson G, **Villalona-Calero M**. ATM participates in topoisomerase II inhibitors induced p21 expression in p53 null cell lines. Proc AACR 2002, abstr 3113, 627
74. Duan W, Ding H, Zhu W, Zilliox L, Srinivasan K, Otterson G, **Villalona-Calero M**. Expression of p16^{ink4a} gene and p21^{WAF1/CIP1} gene in lung adenocarcinomas of the SPC-p53 (273H) transgenic mice. Proc AACR 2002, abstr 4032, 813
75. **Villalona-Calero M**, Monk P, Waite R, Guttridge D, Kuhn J, Otterson G, Rhoades C, Young D, Hauger M, Caligiuri M. Tumor Necrosis Alpha (TNF α) Blockade as an Adjunct to Dose Intense Chemotherapy. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, 2002
76. **Villalona-Calero M**, Duan W, Otterson G, Kleiber B, Hindman K, Shah M, Young D, Wu W, Kuhn J.. Thalidomide Modulation of Irinotecan; an NF-kB Dependent Effect? AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, 2002
77. Lavelle J, **Villalona-Calero M.A**, Shah M, Chan K, Fischer B, Grever M, Otterson G.A. A Phase I Study of Fenretinide Combined with Paclitaxel and Cisplatin for the Treatment of Refractory Solid Tumors. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, 2002
78. Kindwall-Keller T, Otterson G, Rhoades C, Stanek M, Neki A, Criswell T, Hauger M, Soong R, Diasio R, and **Villalona-Calero M**. Phase II evaluation of docetaxel (D) and capecitabine (C) in previously treated non-small cell lung cancer (NSCLC) patients (pts). Proceedings of ASCO, 2003
79. Grainger A, Browning K, Wewers M, Loughlin H, Shapiro C, **Villalona-Calero M**, Ross P, Otterson G. Identifying cancer patients, family members, and a teachable moment for smoking cessation. Proceedings of ASCO, 2003.
80. D. Rizzo, M. **Villalona-Calero, M**. Garrison, G. Schwartz, K. Molpus, P. Monroe, A. Tolcher, L. Hammond, E. K. Rowinsky A pharmacologic and metabolic study of docetaxel (D) administered

on a continuous weekly schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22: 2003 (abstr 651)

81. **Villalona-Calero M**, Otterson G, Wientjes G, Murgo A, Jensen R, Yeh T, Chen D, Song S, Grever M, Au J. Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patients. 10th World Conference in Lung Cancer, 2003
82. **Villalona-Calero M**, Kindwall-Keller T, Soong R, Diasio R, Nuovo G, Otterson G, Criswell T, Neki A, Rhoades C. Phase II study of docetaxel in combination with capecitabine in patients with previously treated non-small cell lung cancer (NSCLC). 10th World Conference in Lung Cancer, 2003
83. Bekaii-Saab T, Lavelle J, Grainger A, Rothrauff S, **Villalona-Calero M**, Otterson G, Ross P. Photodynamic therapy (PDT) can be incorporated into the multimodality treatment of locoregionally advanced non-small cell lung cancer (NSCLC) with obstructive lesions. 10th World Conference in Lung Cancer, 2003
84. Duan W, Gao L, Zhu W, Otterson G, and **Villalona-Calero M**. In vivo expression of human mutant p53-273H does not regulate the expression of p21^{WAF1/CIP1} in p53 null and heterozygous mice. American Association for Cancer Research, 94th Annual Meeting, 2003.
85. Zhu W, Duan W, **Villalona-Calero M**, and Otterson G. Cytotoxicity of 5-aza-2'-deoxycytidine by induction of a DNA damage response pathway. American Association for Cancer Research, 94th Annual Meeting, 2003.
86. Panico K, Duan W, Otterson G, Kleiber B, Hindman K, Shah M, Young D, Wu W, Kuhn J, **Villalona-Calero M**. Phase I and pharmaco-biological study of thalidomide and celecoxib as modulators of irinotecan's anti-cancer activity. Proceedings of the AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, 2003: abst B248, p 6197
87. Duan W, Gao L, Druhan L, Zhu W, Otterson G, **Villalona-Calero M**. Over expression of Pirh2 and concomitant reduction of p53 are associated with lung adenocarcinoma. American Association for Cancer Research, 95th Annual Meeting, 2004.
88. Gao L, Duan W, Zhu W, Otterson G, **Villalona-Calero M**. Gene dosage and aging in lung tumorigenesis in p53 (273H) transgenic mice. American Association of Cancer Research, 95th Annual meeting, 2004.
89. Otterson G, Hileman T, Duan W, Zhu W, **Villalona-Calero M**. Valproic acts as an HDAC inhibitor in cells and works synergistically with the DNMT inhibitor, 5-aza-2'-deoxycytidine. Proceedings of the American Association for Cancer Research Annual Meeting (45) 2004.
90. **Villalona-Calero M**, Gregory Otterson, Guill Wientjes, Ken Kobayashi, Rhonda Jensen, Donn Young, T. Yeh, S. Song, Mike Grever, Jessie Au. Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC). Proceedings of American society of Clinical Oncology, 2004; abstr 7108.
91. **Villalona-Calero M**, T. Sawada, K. Fukino, W. Duan, RM. Brena, N. Williams, C. Plass, C. Eng. Variable responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) may be due to variable somatic EGFR mutational spectra. The third international Chicago Symposium on malignancies of the Chest and Head and Neck. Oct 2004.

92. Otterson G, **Villalona-Calero M**, Grainger A, Hicks W, Murren J, Ellerton J, Mojzisek C, Gerber M, Westaway D. Preliminary Results of a Phase I/II Study of Inhaled Doxorubicin Combined with Docetaxel and Cisplatin for Advanced Non-Small Cell Lung Cancer. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, 2004
93. **Villalona-Calero MA**, Bekaii-Saab T, Burak W, Ross P, Otterson G, Xu Y, Criswell T, Duan W, Young D, Miller J, Kolesar J. Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE Junction adenocarcinomas. American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2005
94. Bekaii-Saab T, Sawada T, Williams N, Frankel W, Plass C, **Villalona-Calero M**, Eng C. Gain-of-function somatic mutations affecting the catalytic domain of EGFR as described in non-small cell lung carcinomas are not present in hepatobiliary tumors, American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2005
95. Bekaii-Saab T, Bender J, Criswell T, Chidiac T, Kosuri K, Young D, Guttridge D, Caligiuri M, **Villalona-Calero M**. A Phase I/II Study of Etanercept and Gemcitabine in Patients with Advanced Stage and Chemotherapy Naive Pancreatic Adenocarcinoma. American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2005
96. Gao L, Duan W, Wu X, Zhang Y, Otterson G, and **Villalona-Calero M**. Differences between the Pirh2 and Mdm2 in Response to DNA Damage. Proceedings American Association of Cancer Research meeting 2005, abstr 3639
97. Gao L, Duan W, Zhang Y, Wu X, Otterson G, and **Villalona-Calero M**. Establishment and characterization of a line of transgenic mice harboring a lung specific human type II p53(175H) mutation. Proceedings American Association of Cancer Research meeting 2005, abstr 1055
98. Chen D, Song S, Wientjes G, Kuang T, Zhao L, Wang J, **Villalona-Calero M**, otterson G, Jensen R, Murgo A, Au J. Low dose suramin as a chemosensitizer in patients: pharmacokinetics, identification and validation of a dosing nomogram. Proceedings American Association for Cancer Research 2005, abstr 3990.
99. J. P. Monk, **M. Villalona-Calero**, J. Dupont, J. Larkin, G. Otterson, D. Spriggs, A. L. Hannah, G. F. Cropp, R. G. Johnson, M. L. Hensley. Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors. Proceedings of American society of Clinical Oncology, 2005. Vol 23, No. 16S, abstr 2049
100. Otterson GA, **Villalona-Calero MA**, Grainger A, Hicks W, Murren J, Schiller J, Gerber M, Ellerton J. Results of a phase I study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer. Proceedings of American society of Clinical Oncology, 2005; abstr 7231.
101. Yee L, Lynch T, **Villalona-Calero M**, Rizvi N, Gabrail N, Sandler A, Cropp G, Palmer G. A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. Proceedings of American society of Clinical Oncology, 2005; abstr 7127.
102. Kosuri K, Bekaii-Saab T, Bender J, Criswell T, Kane Y, Chidiac T, Young D, Guttridge D, Caligiuri M, **Villalona-Calero M**. Disrupting TNF signaling in pancreatic cancer: A phase I/II clinical study

- in patients with advanced disease. Proceedings of American society of Clinical Oncology, 2005; abstr 4103.
103. Bekaii-Saab T, Sawada, N. Williams, W. Frankel, C. Plass, M. **Villalona-Calero**, C. Eng. Intragenic EGFR and EGFR2 mutations in hepatobiliary tumors and potential role in predicting response to agents that target EGFR. Proceedings of American society of Clinical Oncology, 2005; abstr 4037.
 104. **Villalona-Calero MA**, Bekaii-Saab T, Burak W, Ross P, Otterson G, Xu Y, Criswell T, Duan W, Young D, Miller J, Kolesar J. Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE Junction adenocarcinomas. Proceedings of American society of Clinical Oncology, 2005; abstr 4027.
 105. Olencki T, Wientjes G, Otterson G, Saab T, Grainger A, Yeh T, Jensen R, Young D, Au J, **Villalona-Calero M**. Modulation of chemotherapy resistance with low dose suramin in refractory non-small cell lung cancer (NSCLC) patients. A phase I study of sequential non-cross resistant chemotherapy. Proceedings of American society of Clinical Oncology, 2005; abstr 2107.
 106. Grecula J, Grever M, Otterson G, **Villalona-Calero M**, Ross P, Barth R. A Phase I Study of Induction Chemotherapy, Pre-operative Radiotherapy with Motexafin Gadolinium (MGd) and Surgical Resection in Stage IIIA (N2) Non-Small Cell Lung Cancer. Proceedings of the Radiological Society of North America 2005
 107. **Villalona-Calero M**, Duan W, Gao L, Zhang Y, Wu X, Otterson G. Establishment and characterization of a line of transgenic mice harboring a lung specific human type II p53(175H) mutation: a potential model of human disease. Proceedings of the 11th World Conference on Lung Cancer, 2005: abstr. P-128
 108. Rizvi N, **Villalona-Calero M**, Lynch T, Yee L, Gabrail N, Sandler A, Cropp G, Graham M, palmer G. A Phase II study of KOS-862 (Epothilone D) as second line therapy in non-small cell lung cancer. Proceedings of the 11th World Conference on Lung Cancer, 2005: abstr. P-565
 109. Kosuri K, Otterson G, **Villalona-Calero M**, Murren J, Gerber M, Ellerton J. Phase I study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer. Proceedings of the 11th World Conference on Lung Cancer, 2005: abstr. 48
 110. **Villalona-Calero M**, Goel S, Schaaf L, McCracken B, Desai K, Cropp G, Zhou Y, Johnson RG, Hannah A, Shridar M. First-in-Human Phase 1 Trial of a Novel Epothilone, KOS-1584. Accepted for Oral Presentation, American Society of Clinical Oncology Meeting, 2006. abstr 2003 P-79
 111. Miller A, Murry D, Hollis D, Owzar K, Lewis L, Kindler H, Marshall J, **Villalona-Calero, M**, Edelman M, Ratain M. Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101. Proceedings of American Society of Clinical Oncology, 2006; abstr 3026. P-127
 112. Mrozek E, Kolesar J, Allen J, Young D, Angus D, Kendra K, Rhoades C, **Villalona-Calero M**, Shapiro C. Phase II study of sequentially administered mitomycin (MMC) and irinotecan (CPT-11) in patients (pts) with metastatic breast cancer (MBC). Proceedings of American Society of Clinical Oncology, 2006; abstr 10542. P-571
 113. Otterson G, **Villalona-Calero M**, Ellerton J, Westaway D, Mirjam G, Murren J. Phase I/II study of Inhaled Doxorubicin Combined with Platinum Based Therapy for Advanced NSCLC. 4th

- International Chicago Symposium on Malignancies of the Chest and Neck & Head, Oct 2006, abstr 4.01.20, pp: 899
114. **Villalona-Calero M**, Duan W, Gao L, Wu X, Otterson G. Establishment of Lung Cancer Transgenic Animal Models with Type Specific P53 Mutants for Experimental Therapeutics Studies. 4th International Chicago Symposium on Malignancies of the Chest and Neck & Head, Oct 2006, abstr 4.04.04, pp: 909
 115. Otterson G, **Villalona-Calero M**, Ellerton J, Westaway D, Mirjam G, Murren J. Phase I/II study of Inhaled Doxorubicin Combined with Platinum Based Therapy for Advanced NSCLC. 4th International Chicago Symposium on Malignancies of the Chest and Neck & Head, Oct 2006, abstr 4.01.20, pp: 899
 116. **Villalona-Calero M**, Duan W, Gao L, Wu X, Otterson G. Establishment of Lung Cancer Transgenic Animal Models with Type Specific P53 Mutants for Experimental Therapeutics Studies. 4th International Chicago Symposium on Malignancies of the Chest and Neck & Head, Oct 2006, abstr 4.04.04, pp: 909
 117. **Villalona-Calero M**, Goel S, Schaaf L, McCracken B, Desai K, Cropp G, Kersey K, Johnson R, Hannah A, Mani S. Safety and Pharmacokinetic Trial of KOS-1584, a Novel Analog of Epothilone D. Proceedings of the 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics. (18):A634, Prague Czech Republic Nov 2006
 118. Wenrui Duan, Li Gao, Xin Wu, Gregory A. Otterson, **Miguel A. Villalona-Calero**. Expression of a mutant p53 in lung specific transgenic mice cause an age-related demographic shift in lung tumor incidence. Proceedings of the American Association for Cancer Research Annual Meeting, abstr 3875, 2007.
 119. Li Gao, Wenrui Duan, Xin Wu, Gregory A. Otterson, **Miguel A. Villalona-Calero**. Human mutant p53 lung cancer cells respond differently to PRIMA-1 induced apoptosis. Proceedings of the American Association for Cancer Research Annual Meeting, abstr #.4879, 2007.
 120. Miller AA, Murry DJ, Owzar K, Hollis DR, Abou-Alfa GK, Desai A, Hwang J, **Villalona-Calero M**, Dees EC, Lewis LD, Ratain MJ. Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. Proceedings of American Society of Clinical Oncology, 2007; abstr 3538. P-147
 121. Hill M, Campbell A, Kosuri J, **Villalona M**, Bekaii-Saab. A phase I dose escalation study of pharmacobiologically based scheduling of capecitabine and mitomycin C (MMC) in patients with gastrointestinal solid malignancies. Proceedings of American Society of Clinical Oncology, 2007; abstr 15154. P-646
 122. Arce-lara C, Cataland S, Brady C, Kraut E, Otterson G, **Villalona-Calero M**, Bekaii-Saab T. A single center review of the experience with mitomycin C (MMC) and the risk of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS). Proceedings of American Society of Clinical Oncology, 2007; abstr 15167. P-647
 123. McCann J, Fossella F, **Villalona-Calero M**, Tolcher A, Fidias P, Raju R, Zildjian S, Guild R, Fram R. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-

- positive small cell carcinoma. Proceedings of American Society of Clinical Oncology, 2007; abstr 18084. P-690
124. Li Gao, Wenrui Duan, Xin Wu, Li Wang, Gregory A. Otterson, **Miguel A. Villalona-Calero**. PRIMA-1 stabilizes p53 by altering phosphorylation to induce apoptosis in human lung cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting, abstr #5656, 2008.
 125. Wenrui Duan, Li Gao, Xin Wu, Li Wang, Erinn M. Hade, Jian-Xin Gao, Sanford H. Barsky, Gregory A. Otterson, **Miguel A. Villalona-Calero**. Mutant p53 collaborating with K-ras gene mutations and p16INK4a promoter methylation result in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. Proceedings of the American Association for Cancer Research Annual Meeting, abstr # 2960, 2008.
 126. Joseph Markowitz, Charis Eng, Wolfgang Sadee, Nyla Heerema, Xiaobai Li, Angela Campbell, Kristy Culler, Bert O'Neil, Ruey-min Lee, Mark Zalupski, Janet Dancey, Michael Grever, **Miguel Villalona-Calero**, Tanios Bekaii-Saab. A Phase II study of the efficacy and tolerability of Lapatinib in patients with advanced hepatocellular carcinomas. Proceedings of the American Association for Cancer Research Annual Meeting, 2008.
 127. Lutsberg M, Bekaii-Saab T, Diasio R, Ezzeldin H, Starrett S, Otterson G, **Villalona-Calero, M.** Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemo-naïve non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 26: 2008 (May 20 suppl; abstr 19090)
 128. Karpenko M, Liu Z, Aimiwu J, Wang L, Wu X, **Villalona-Calero M**, Young D, Chan K, Grever M, Otterson G. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in patients with NSCLC. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3502). Oral presentation.
 129. Otterson G, Wang L, Wu X, Duan W, Gao L, Karpenko M, **Villalona-Calero M**. Effect of dichloroacetate in combination with chemotherapy on human lung cancer cells. J Clin Oncol 26: 2008 (May 20 suppl; abstr 14637)
 130. William A. Hall, Li Wang, James W. Clarke, Gregory A. Otterson, Jian Z. Wang, **Miguel Villalona-Calero**, Tien Hoang, Nina A. Mayr, Patrick Ross, John C. Grecula. Modulation of radiation response of non-small cell lung cancer cells with poly (ADP-Ribose) polymerase inhibitor ABT-888. Proceedings of ASTRO, Sept 2008.
 131. **Villalona-Calero M**, Balint C, Otterson G, Shapiro C, Bekaii-Saab T, Cohn D, Byrd J, Marcucci G, Hicks W, Shah M, Chiocca E, Chan K, Blum W, Sadee W, Schaaf L, Knopp M, Grecula J, Young D, Grever M, Balcerzak S. NCI supported Early Therapeutics Program with Phase II intent at the Ohio State University (N01 CM-62207). NCI Translates, NCI Translational Science Meeting, Washington DC, November 2008.
 132. Grever M, Balint C, Blum KA, Blum W, Byrd JC, Carson WE, Chan K, Chen C-S, Cohn D, Fischer B, Grecula JC, Johnson AJ, Kefauver C, Knopp MV, Lesinski GB, Lucas DM, O'Malley D, Marcucci G, Otterson GA, Phelps MA, Schaaf LJ, Thomas J, **Villalona-Calero MA**, and Wilkins D. Phase I Clinical/Translational Trials of Anti-Cancer Agents: The Ohio State University. NCI Translates, NCI Translational Science Meeting. Washington DC, November 2008.
 133. Blum W, Klisovic R, Liu S, Garzon R, Kefauver, Liu Z, Mickle J, Devine H, Devine S, Grever M, Chan K, **Villalona-Calero M**, Byrd J and Marcucci G. Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age \geq 60) with Previously Untreated Acute

- Myeloid Leukemia (AML). American Association of Hematology Annual Meeting 2008, abstr 2957.
134. Duan W, Gao L, Wu X, Cohn D, O'Malley D, Dial L, Otterson G, and **Villalona-Calero M**. Analysis of FANCD2 protein monoubiquitin status and nuclear foci formation in ovarian cancers. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, 2009 (abstr 1019).
 135. Gao L, Duan W, Wu X, Otterson G, and **Villalona-Calero M**. PRIMA-1 regulates microRNA 34A to promote apoptosis in human lung cancer cells. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, 2009 (abstr 5586).
 136. Tanios Bekaii-Saab, Mitch Phelps, Xiaobai Li, Motoyasu Saji, Kavitha Kosuri, Laura Goff, John Kauh, Bert O'Neil, Christopher South, James Thomas, Stephanie Balsom, Nicole Chattah, Catherine Balint, Ryan Lierseemann, Vasily Vasko, William Marsh, L. Austin Doyle, Matthew Ringel, **Miguel A. Villalona**. A Multi-institutional Study of AZD6244 in Patients with Advanced Biliary Cancers. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research 2009 (late breaking abstract)
 137. Mitch A. Phelps, Danxin Wang, Josephine E. Aimiwu, Sherri L. Starrett, Audrey C. Papp, Ahmed A. Ghany, William J. Hicks, Kavitha V. Kosuri, Gregory A. Otterson, Mark A. Socinski, Thomas E. Stinchcombe, Weiqiang Zhao, Larry J. Schaaf, Sanford H. Barsky, Kenneth K. Chan, Wolfgang Sadee, **Miguel A. Villalona-Calero**. Erlotinib in African Americans with lung cancer: a prospective, clinical, molecular, pharmacokinetic and pharmacogenetic characterization. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, 2009 (abstr 6577).
 138. M. B. Lustberg, J. Nuovo, J. P. Thomas, P. J. Monk III, S. Kim, **M. Villalona-Calero**, T. Bekaii-Saab. Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. *J Clin Oncol* 27:15s, 2009 (suppl; abstr 2569)
 139. W. G. Blum, R. Klisovic, S. Liu, C. Kefauver, M. R. Grever, L. Schaaf, K. Chan, J. C. Byrd, **M. Villalona-Calero**, G. Marcucci. Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older. *J Clin Oncol* 27:15s, 2009 (suppl; abstr 7010)
 140. Aimee Ruder, Marlo Blazer, Jessica Poirier, Weiqiang Zhao, **Miguel A. Villalona-Calero**. TR39. Evaluation of erlotinib-related toxicities in lung cancer patient with EGFR mutations. IASLC-International Association for the Study of Lung Cancer, The 13th World Conference on Lung Cancer, San Francisco, CA, August 2009.
 141. F. Fossella, PJ Woll, P Lorigan, A Tolcher, M O'Brien, J O'Keeffe, S Zildjian, A Qin, J O'Leary, and **M Villalona-Calero**. Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC). IASLC- International Association for the Study of Lung Cancer, The 13th World Conference on Lung Cancer, San Francisco, CA, August 2009.
 142. P.J. Woll, P. Lorigan, M. O'Brien, **M. Villalona-Calero**, R.A. Mastico, R.J. Lutz, C. Carrigan, J. O'Keeffe, A. Qin, J. O'Leary, and F.V. Vossella. Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC). AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, Boston, MA, November 2009.

143. Duan W, Gao L, Wu X, Zhao W, Leon M, Otterson G, and **Villalona-Calero M**. Functional analysis of the Fanconi Anemia pathway in primary lung tumors. Proceedings of the 101 Annual Meeting of the American Association for Cancer Research, Washington DC, 2010 (abstr 3750)
144. Phelps M, Cohn D, O'Malley D, Wei L, Wilkins D, Campbell A, Schaaf L, Coffey M, **Villalona-Calero M**, Grever M, Nuovo G, Zwiebel J. Reovirus replication in ovarian and peritoneal tumors after intravenous administration. Proceedings of the 101 Annual Meeting of the American Association for Cancer Research, Washington DC, 2010 (abstr 2594)
145. Zhao W, Duan W, Leon M, Chen A, Sofletea G, Thurmond J, Ramaswamy B, O'Malley D, Bekaii-Saab T, **Villalona-Calero M**. Targeting fanconi anemia (FA) repair pathway deficiency for treatment with PARP inhibitors. J Clin Oncol 28:23s, 2010 (suppl; abstr TPS168)
146. Cohn D, Nuovo G, Coffey M, O'Malley D, **Villalona-Calero M**, Grever M, Deam D, Zwiebel J, Phelps M. Phase 1/11 trial of reovirus serotype 3-dearing strain in patients with recurrent ovarian cancer. J Clin Oncol 28:44s, 2010 (suppl; abstr TPS253)
147. Bertino E, Otterson G, **Villalona-Calero MA**, Nana-Sinkam SP, Ghany AM, Donthireddy KR, Abdel-Karim N, Cantrell S, Phillips GS. Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies. J Clin Oncol 28:54s, 2010 (suppl; abstr TPS291)
148. Lam ET, Otterson G, Donthireddy K, Thurmond J, Hade E, Coffey M, **Villalona-Calero M**. Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors. J Clin Oncol 28:54s, 2010 (suppl; abstr TPS292)
149. Janne P, Wang X, Socinski M, Crawford J, Capelletti M, Edelman M, **Villalona-Calero M**, Kratzke R, Vokes E, Miller V. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never of light former smokers with advanced lung adenocarcinoma; CALGB 30406. J Clin Oncol 28:539s, 2010 (suppl; abstr 7503)
150. **Villalona-Calero MA**, Stinchcombe T, Phelps M, Starrett S, Papp A, Ghany A, Hicks W, Otterson G, Socinski M, Zhao W. Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC. J Clin Oncol 28:555s, 2010 (suppl; abstr 7569)
151. Duan W, Gao L, Vereb G, Wu X, Otterson G, **Villalona-Calero M**. Regression of Spontaneous Non-small Lung Cancer in P53 Mutant Transgenic Mice Following Exposure to PRIMA-1. AACR 102nd Annual Meeting 2011 in Orlando, FL. Cancer Research. 2011; 71:610. April 2011 (abstr 610).
152. Gao L, Duan W, Otterson G, **Villalona-Calero M**. Inhibition of Poly (ADP-ribose) Polymerase in Lung Cancer Cells with Defective Fanconi Anemia (FA) Pathway. AACR 102nd Annual Meeting 2011 in Orlando, FL. Cancer Research; 71:5500. April 2011 (abstr 5500).
153. Bauer T M, Bekaii-Saab T, Li X, **Villalona-Calero M**, Philip P A, Shields AF, Zalupski M M, Hammad N, El-Rayes B F. CA19-9 predicts efficacy of chemotherapy in patients with advanced pancreas cancer: A pooled analysis of six prospective trials. 47th ASCO Annual Meeting in Chicago, IL. (abst 80453)

154. Bertino E M, Zhao W, **Villalona-Calero M**, Abdel Karim NF, Shilo K, Otterson G. EML4-ALK in NSCLC: The OSU Experience. 47th ASCO Annual Meeting in Chicago, IL. (abstr 83917)
155. Kendra K, Plummer R, Salgia R, O'Brien MER, Paul EM, Suttle AB, Ottesen LH, **Villalona-Calero M**. Phase I Dose-Finding Study for Pazopanib (P) and Paclitaxel (T) in Combination in the First-line Setting in Patients (pts) with Advanced Solid Tumors. Proceedings of the European Society of Medical Oncology Meeting 2011, Abstr.
156. Janne P, Wang X, Socinski M, Crawford J, Gu L, Capelletti M, Edelman M, **Villalona-Calero M**, Kratzke R, Vokes E, Miller V. Outcome of Advanced NSCLC Patients with EGFR Exon 19 and 21 Mutations Treated with Erlotinib (E) Alone or in Combination with Carboplatin/Paclitaxel (CP) in CALGB 30406. Journal of Thoracic Oncology. Vol. 6. Proceedings of the 14th World Conference on Lung Cancer. July 2011.
157. **Villalona-Calero M**, Lam E, Otterson G, Zhao W, Donthireddy K, Thurmond J, Hade E, Pennington J, Mettinger K, Coffey M. Phase II Study of Reovirus with Paclitaxel (P) and Carboplatin (C) in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Kras or EGFR-Activated Tumors. Journal of Thoracic Oncology. Vol. 6. Proceedings of the 14th World Conference on Lung Cancer – mini oral presentation. July 2011.
158. Duan W, Gao L, Otterson G. **Villalona-Calero M**. Targeting Mutant P53 in Non-Small Lung Cancer with PRIMA-1. Journal of Thoracic Oncology. Vol. 6. Proceedings of the 14th World Conference on Lung Cancer. July 2011.
159. Otterson G, Bertino E, Karim N, Donthireddy K, Ghany A, Rupert R, Cantrell S, Rahmani M, Lynn M, Nana-Sinkam SP, Phillips G, **Villalona-Calero M**. Phase II Trial of Nabpaclitaxel Plus Carboplatin in Patients with Advanced NSCLC at Risk of Bleeding from VEGF Directed Therapies. Journal of Thoracic Oncology. Vol. 6. Proceedings of the 14th World Conference on Lung Cancer. July 2011.
160. Kendra KL, Plummer R, Salgia R, O'Brien M, Paul EM, Suttle AB, Ottesen LH, **Villalona-Calero M**. Phase I dose finding study for pazopanib and paclitaxel in combination in the first-line setting in patients with advanced solid tumors. ESMO, 2011, Abstract #1207.
161. Ramaswamy B, Srividya V, Mullins D, Cathothers S, Young G, Wenrui D, Zhao W, Lustberg M, Leon M, Wesolowski R, Layman R, Mrózek E, Shapiro CL, **Villalona-Calero M**. Prevalence of Dysfunctional Fanconi Anemia (FA) DNA Repair Pathway in Breast Cancer. Poster discussion presented at the 2011 Annual Meeting of the San Antonio Breast Cancer Symposium in San Antonio Texas. PD 10-01
162. Kummar S, Oza A, Fleming G, Sullivan D, Gandara D, Erlichman C, **Villalona-Calero MA**, Morgan R, Chen A, Ji J, Allen D, Lih C, Steinberg S, Williams P, Conley B, Doroshow J. Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. J Clin Oncol 30, 2012 (suppl; abstr 5020)
163. Ramaswamy B, Lustberg M, Wesolowski R, Layman R, Mrozek E, Olson E, Andreopoulou E, Garcia-Villa A, Chalmers J, Cotrill J, Nutter J, Ledin J, Schaaf L, Bajestani S, Zhao W, Geyer S, Chen A, Shapiro C, **Villalona-Calero MA**, Knopp M, Grever M. Phase I study of PARP inhibitor

- ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609). Proceedings of the 2012 AACR annual meeting, abstr. 5586
164. Bertino E, **Villalona-Calero MA**, Nana-Sinkam P, Cantrel S, Rahmani M, Symmes C, Phillips G, Otterson G. Phase 2 Trial of *nab*-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies. Proceedings of the 2012 AACR annual meeting. Late Breaking abstr-225
165. Duan W, Gao L, Brooks C, Kalvala A, Wu X, Otterson G, **Villalona-Calero MA**. Establishment of P53 mutant type specific spontaneous lung tumor in transgenic mice for treatment. Proceedings of the 2012 AACR Annual Meeting, abstr 4740
166. Kummar S, Oza A, Fleming G, Sullivan D, Gandara D, Erlichman C, **Villalona-Calero M**, Morgan R, Chen A, Ji J, Allen D, Lih C, Steinberg S, Williams P, Conley B, Doroshow J. Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. Proceedings of the 2012 ASCO Annual Meeting, June 2012, Abstr. 5020.
167. **Villalona-Calero M**, Lam E, Otterson G, Zhao J, Timmons M, Subramaniam D, Hade E, Gill G, Coffey M, Bertino E. Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors. Proceedings of the 24th EORTC-NCI-AACR Symposium on Molecular Target and Cancer Therapeutics, European Journal of Cancer, Volume 48, Suppl. 6, November 2012, abstr. 603.
168. **Villalona-Calero M**, Duan W, Zhao W, Shilo K, Ji J, Thurmond J, Norris A, Rose J, Layman R, Marshall J, Bekaii-Saab T, Chen A. Phase I trial of veliparib or mitomycin (MMC) + veliparib in patients with sporadic solid tumors screened for somatic deficiency in the Fanconi Anemia (FA) pathway. Proceedings of the 2013 AACR Annual Meeting, abstr 4740. Abstr Late Breaking 139.
169. Singh M, Leasure J, Chronowski C, Li N, Bondra K, Duan W, **Villalona M**, Vergis A, Hensley L, Kaplon R, Geier B, Kurmasheva R, Woods G, Hammond S, Houghton P, Pelloski C. Targeting FANCD2 as a radiosensitizer in pediatric rhabdomyosarcoma. Proceedings of the 2013 AACR Annual Meeting, abstr 4439.
170. Kalvala A, Gao L, Barnwel B, Otterson G, **Villalona Calero M**, Duan W. Mutations in Rad51C in colon tumors. Proceedings of the 2013 AACR Annual Meeting, abstr 4221.
171. Gao L, Duan W, Barnwell B, Kalvala A, Otterson G, **Villalona-Calero M**. Sensitivity of small cell lung cancer cells with defective Fanconi Anemia (FA) pathway to BCL2 inhibitors. Proceedings of the 2013 AACR Annual Meeting, abstr 4365.
172. Duan W, Rees T, Vu K, Barnwell B, Gao L, Kalvala A, Wu X, Otterson G, **Villalona-Calero M**. Promoter hypermethylation and gene expression of FANCF in non-small cell lung cancer (NSCLC). Proceedings of the 2013 AACR Annual Meeting, abstr 4246.
173. Stinchcombe T, Sholl L, Wang X, Gu L, Socinski M, Rodig S, Capelletti M, Crawford J, Edelman M., **Villalona-Calero M**, Kratzke R, Vokes E, Miller V, Janne P. An analysis of the prevalence of *HER2* and *KRAS* mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer

- (NSCLC). 2013 ASCO Annual Meeting Proceedings Errata. *J Clin Oncol* 31, 2013 (suppl; abstr 8039)
174. Ramaswamy B, Zhang J, Hall N, Schregel K, Lustberg M, Wesolowski R, Mrozek E, Layman R, Olson E, Ottman S, Camp A, Chalmers J, Geyer S, **Villalona-Calero M**, Shapiro C, Grever M, Knopp M. NCI 8609: Interim fluoro-3'-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer. 2013 ASCO Annual Meeting Proceedings. *J Clin Oncol* 31, 2013 (suppl; abstr 1023)
 175. **Villalona-Calero M**, Lam E, Zhao W, Otterson G, Subramaniam D, Chao B, Timmons M, Schaaf L, M Gill G, Coffey M. Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors. 15th World conference in lung cancer. P1.11-026, 2013
 176. Duan W, Gao L, Kalvala A, Brooks C, Barnwell B, Mo X, Ding H, Shilo K, Otterson G, and **Villalona-Calero M**. Type of P53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung specific transgenic mice. 15th World conference in lung cancer, 2013.
 177. Chen W, Brodsky S, Zhao W, Otterson G, **Villalona-Calero M**, Satoskar A, Hasan A, Pelletier R, Ivanov I, Ross P, Nadasdy T and Shilo K. Y-Chromosome Status Identification Suggests a Recipient Origin of Post-Transplant Non-Small Cell Lung Carcinomas: Chromogenic in situ Hybridization Analysis. United States College of Pathology meeting. San Diego. 2014
 178. Kalvala A, Gao L, Barnwell B, Otterson G, **Villalona-Calero M**, and Wenrui Duan. Identification of a Novel Rad51c-ATXN7 fusion gene in colorectal tumors. 2014 AACR Annual Meeting, p2407
 179. Gao L, Barnwell B, Kalvala A, Otterson G, Duan W and **Villalona-Calero M**. Combined BCL-2/XL and mTor Inhibition Promotes Apoptosis in Small Cell Lung Cancer. 2014 AACR Annual Meeting, p5434.
 180. J. C. Grecula, S. Elias, K. Thelen, M. Knopp, G. Otterson, P. Ross, E. Kassis, M. Welliver, M. **Villalona-Calero, K.** Shilo, S. Lo, G. Jia, W. C. Yu, B. Yuh, S. Ghosh, E. Bertino, N. Mayr. Dynamic-Contrast Enhanced MR and Volume Regression rate as a preoperative predictive assay in patients with Non Small Cell Lung Cancer, 2014 ASTRO meeting.
 181. Bertino E, McMichael E, **Villalona-Calero M**, Grever M, Carson W, Otterson G. Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with lenalidomide in advanced solid tumors: A phase 1 trial. 2014 ASCO annual meeting. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 3044).
 182. Wesolowski R, Zhao M, Geyer S, Lustberg M, Mrozek E, Layman R, Macrae E, Zhang J, Hall N, Schregel K, Ottman S, Camp A, Chalmers J, Andreopoulou E, **Villalona-Calero M**, Shapiro C, Knopp M, Grever M, Ramaswamy B. Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC). 2014 ASCO annual meeting. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 1074)
 183. Camidge D, Ou S, Shapiro G, Otterson G, Villaruz L, **Villalona-Calero M**, Iafrate A, Varella-Garcia M, Dacic S, Cardarella S, Zhao W, Tye L, Stephenson P, Wilner K, James L, Socinski M. 2014 ASCO annual meeting. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 8001)

184. Monk P, Liu G, Stadler W, Geyer S, Sexton J, Wright J, **Villalona-Calero M**, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Cooney M, Dawson N, George S, Garcia J. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (mCRPC). ASCO GU Symposium 2015.

Oral Presentations in National/International Meetings

1. Oncolytic reovirus in combination with paclitaxel/carboplatin in NSCLC patients with RAS activated malignancies, long-term results. 16th World Conference on Lung Cancer. Denver Colorado September 2015.
2. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors with Functional Deficiency in Homologous Recombination Repair. Cancer Therapy and Evaluation Program annual meeting. Bethesda, Maryland. October 2014.
3. University of Alabama, Birgminham Grand Rounds. “DNA repair as an anticancer target” May 2014.
4. Karmanos Cancer Center, Detroit Michigan Grand Rounds. “DNA repair as an anticancer target” April 2014.
5. Phase I trial of veliparib or mitomycin (MMC) + veliparib in patients with sporadic solid tumors screened for somatic deficiency in the Fanconi Anemia (FA) pathway. Minisimposium, American Association of Cancer Research 2013 meeting, Washington DC, April 2013.
6. Invited Speaker. “The latino population and cancer, challenges for the health care provider.” Oncology Nursing Society, Columbus, Ohio, October 10, 2012.
7. The Ohio State University, Department of Pathology Grand Rounds. “Molecular targeted agents in solid tumor oncology”. Nov 8, 2011
8. Roswell Park Cancer Institute Grand Rounds. “Challenging Targets in Solid Tumor Oncology” Oct 28, 2011.
9. The Ohio State University, Dept of Internal Medicine Grand Rounds. “Molecular targeted agents in solid tumor oncology; a new era for the practicing clinician”. Sept 1, 2011.
10. Key note address. CEDIMAT chemotherapy unit inauguration. “The Evolution of Cancer Treatment”. Santo Domingo Dominican Republic, August 25, 2011.
11. Invited Speaker. “Cáncer del Pulmón: Patogenia y Estadiaje.” Society Congress. Congreso Neumología República Dominicana. Santo Domingo, Dominican Republic. May 2011.
12. Invited Speaker. “Logros en la Personalización del Tratamiento del Cáncer Pulmonar.” Society Congress. Congreso Neumología República Dominicana. Santo Domingo, Dominican Republic. May 2011.
13. Invited Speaker – Co-Chair. “Can Advancing our Understanding of the Human Genome Reduce Breast Cancer Health Disparities?” MICR Scientific Symposium. Proceeding of AACR 102nd Annual Meeting. Orlando, FL April 2011.
14. Invited Speaker. “Phase I trial of veliparib or Mitomycin C + veliparib in solid tumor patients with Fanconi DNA repair defects.” Spring 2011 CTEP Early Drug Development Meeting – Washington NCI. Bethesda, MD. March 2011.
15. Invited Speaker. “Challenging Targets in Solid Tumor Oncology.” Grand Rounds, Cleveland Clinic. Cleveland, OH. March 2011.
16. Invited Speaker. “Lung Cancer: New Diagnostic and Treatment Options.” 2011 Puerto Rico Chapter Scientific Meeting - American College of Physicians. San Juan, Puerto Rico. February 2011.
17. Invited Speaker. “Difficult Cancer Targets.” Department of Pharmacology Seminar/Journal Club. Ohio State University. Columbus, OH. November 2010.
18. Invited Speaker. “Difficult Cancer Targets in Lung Cancer.” Lung Cancer Conference 2010. Ohio State University, Columbus, OH. November 2010.
19. Invited Speaker. “A Latino in the Heart of it all.” 2nd Annual Ohio Latino Cancer Summit, Glenwood United Methodist Church, Columbus, OH. September 2010.

20. Invited Speaker. "Modulation of Anticancer Agents in the Clinic". Grand Rounds, Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia. October 2009.
21. Invited Speaker. "Science in lung cancer: Where are we, and where are we going?" Jornada UCE-Universidad Central del Este, Santo Domingo, Dominican Republic. October 2009.
22. Invited Speaker. "Comprehensive management of early stage lung cancer". Jornada UCE-Universidad Central del Este, Santo Domingo, Dominican Republic. October 2009.
23. Key Note Speaker. Conferencia Magistral del Egresado, Dr Manuel Felipe Pimentel Imbert: "Lung Cancer in the non-smoker, Molecular Biology Clinically Applied". Universidad Nacional Pedro Henríquez Ureña Medical School, Santo Domingo, Dominican Republic. April 2009.
24. Speaker and Co-Chair. The Molecular Biology of Lung Cancer in Never Smokers: a Different Disease. New Concepts in Organ Site Research, American Association for Cancer Research, Denver, Colorado. April 2009.
25. Discussant and Chairperson. Clinical Trials 3, Mini-symposium. American Association for Cancer Research, Denver, Colorado. April 2009.
26. Chair-person and Moderator. Cancer Drug Development as a Successful Public-Private Enterprise: The NCI in Partnership with Industry. Science Policy Forum. American Association for Cancer Research, Denver, Colorado. April 2009.
27. Invited Speaker. Epidemiología, patología y manejo del cancer de pulmon, enfermedad Temprana. Jornada del Cancer del pulmon. Universidad Central del Este, San Pedro de Macoris, Dominican Republic. November 2008
28. Invited Speaker. Manejo del cancer de pulmon, enfermedad avanzada. Jornada del Cancer del pulmon. Universidad Central del Este, San Pedro de Macoris, Dominican Republic. November 2008
29. Key Note Speaker. El mosquito y el coronel. Jornada del Cancer del pulmon. Universidad Central del Este, San Pedro de Macoris, Dominican Republic. November 2008
30. Invited Speaker. Modulation of Anticancer Agents in the Clinic: Challenges and opportunities. Grand Rounds, Simon Cancer Center Indiana/Purdue University, Indianapolis, Indiana. August 2008,
31. Invited Speaker. Modulation of Anticancer Agents in the Clinic: Challenges and opportunities. American Association for Cancer Research Centennial Conference in Translational Research, Monterrey California. July 2008
32. Invited Speaker. Tyrosine Kinase Inhibitors in Lung Cancer. Special Grand Rounds, Pennsylvania State University. June 2008
33. Invited Speaker. Treatment of Lung Cancer. Annual Meeting of the Dominican Society of Hematology and Oncology, Punta Cana, Dominican Republic. April 2008
34. Invited Speaker. Predictive Factors of Response to EGFR Tyrosine Kinase Inhibitors. Cancer Center Grand Rounds, The Ohio State University Columbus, OH. February 2008
35. Invited Speaker. EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Special Grand Rounds, Mayo Clinic Jacksonville. January 2008
36. Invited Speaker, Predictive Factors of Response to EGFR Tyrosine Kinase Inhibitors. Grand Rounds UAB Birmingham, Alabama. October 2007
37. Invited Speaker, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Clinical and Molecular Predictors of Response. Grand Rounds Barbara Ann Karmanos Cancer Institute. Detroit, Michigan. April 2007
38. Invited Speaker, Epidermal Growth Factor Receptor Inhibitors in Lung Cancer; Clinical and Molecular Predictors of Activity. Pharmacology and Drug Discovery/Development in the Era of Genomics Symposium. Columbus, Ohio. March 2007
39. Invited Speaker, Predictive Factors of Response to EGFR Inhibitors. 21st century Care for Lung Cancer Symposium, Columbus Ohio. March 2007

40. Invited Speaker, Prognostic and Predictive Factors in Colorectal Cancer. The 2nd Messina Conference in Cancer Pharmacogenomics. Sicily, Italy. January 2007
41. Invited Speaker, "TNF in cancer, friend or foe?" Human Biology Grand Rounds, Fred Hutchinson Cancer Research Center, Seattle, Washington. October 2006
42. Invited Speaker, "Non small cell lung cancer: Advances in treatment". Southeast Chapter of Oncology Nurses Society, Fall Conference, Ohio University, Zanesville Campus Center, Zanesville, Ohio. September, 2006
43. Invited Speaker, "Latinos in the U.S.: Cultural sensitivity issues and their impact in health care." Key note speaker, Ohio University, Athens, Ohio. June, 2006
44. Platform Presentation. "First-In-Human Phase I trial of a Novel Epothilone, KOS-1584." American Society of Clinical Oncology, 42nd Annual Meeting, Atlanta, GA, June, 2006
45. Keynote Speaker, "Tyrosine kinase inhibitors in lung cancer therapy." Novel Therapies in Thoracic Oncology Symposium, University of Minnesota Medical School. July, 2005
46. Invited Speaker, "Advances in the treatment of non-small cell lung cancer." Sylvester Comprehensive Cancer Center, Grand Rounds, University of Miami, Miami, Florida. December 2004
47. Invited Speaker, "Cachexia in pancreatic cancer molecular mechanisms and potential practical approaches". Advances in the multidisciplinary management of pancreatic disease Symposium, The Ohio State University Comprehensive Cancer Center and Department of Surgery, Columbus Ohio. September 2004
48. Plenary Presentation. "Variable responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) may be due to variable somatic EGFR mutational spectra." , The third international Chicago Symposium on malignancies of the Chest and Head and Neck. October 2004
49. Invited Speaker, "The Hispanic/Latino patients, cultural implications in health care." The Susan G. Komen Breast Cancer Foundation, Columbus, Ohio. January 2004
50. Invited Speaker, "Chemotherapy for thoracic malignancies." The Ohio State University Continuing Medical Education Webcast for the 21st century, Columbus, Ohio. January 2004
51. Invited Speaker. "Modulation of chemotherapy agents at the molecular level: A potentially beneficial strategy in advanced thoracic malignancies." Rushing against thoracic malignancies conference, The Ohio State University, Columbus, Ohio. September, 2003
52. Invited Speaker, "New therapies for colon cancer." School of Pharmacy, University of Wisconsin, Twenty-Fourth Annual Madison Clinical Conference, Advances and Controversies in Oncology Pharmacotherapy. Madison, Wisconsin. March, 2003
53. Invited Speaker, "Tumor Necrosis Factor In Cancer, Friend or Foe?" Department of Interdisciplinary Oncology Grand Rounds, Lee Moffit Cancer Center, Tampa Florida. July 2002
54. Invited Speaker, "TNF blockade as an adjunct to cancer therapy." Internal Medicine Grand Rounds, The Ohio State University, Columbus, Ohio. July 2002
55. Invited Speaker, Newer schedules with Capecitabine/Docetaxel." Satellite Symposium, Miami Breast Cancer Conference, Miami, Florida. March, 2002
56. Invited Speaker, "Newer schedules with Capecitabine/Docetaxel." Satellite Symposium, San Antonio Breast Cancer Conference, San Antonio, Texas. December 2001
57. Invited Speaker, "TNF receptor blockade in cancer therapy." University of Arizona Cancer Center Grand Rounds, Tucson Arizona. October, 2001
58. Invited Speaker, "TNF receptor antibodies for management of cancer associated fatigue/cachexia." Congress on Monoclonal Antibodies in Cancer, Alberta, Canada. September 2001

59. Invited Presentation. "Phase I study of Suramin/Paclitaxel carboplatin in patients with advanced non-small cell lung cancer." Cancer Therapy and Evaluation Program Drug Development meeting, National Cancer Institute, Bethesda MA. September 2001
60. Invited Speaker, "A novel strategy to revert Paclitaxel resistance in patients with non-small cell lung cancer." Cancer and Leukemia Group B, Fall meeting, Amelia Island Plantation, Jacksonville Florida. September 2001
61. Invited Speaker, "Pharmacologically based Phase I study of Irinotecan and mitomycin-C in patients with solid malignancies." The University of Texas, M.D. Anderson Cancer Center Investigators' Workshop, Colorado Springs, Colorado. July, 2001
62. Invited Speaker, "Highlights of the 2001 ASCO meeting: Colorectal Cancer". , The Columbus Community Clinical Oncology Program, Columbus, Ohio. June, 2001
63. Keynote speaker, "Progress and opportunity in cancer research". Ohio University, Zanesville Campus, Ohio. March 2001
64. Invited Speaker, "Exploiting pharmacologic interactions of anticancer drugs at the molecular level." Medical Oncology Grand Rounds, University of Minnesota. February 2001
65. Invited Speaker, "Treatment of non-small cell lung cancer: The present and the future." Medical Oncology Grand Rounds, University of Cincinnati, Cincinnati, Ohio. February, 2000
66. Guest Professor, "New Drugs in the treatment of stomach cancer." XIII Oncology Centroamerican and Caribbean Congress and Integrated Congresses, Tegucigalpa, Honduras. November 2000
67. Guest Professor, "New Drugs in the treatment of colorectal cancer" XIII Oncology Centroamerican and Caribbean Congress and Integrated Congresses. Tegucigalpa, Honduras. November 2000
68. Invited Speaker. "Capecitabine and the taxanes: Synergy or speculation?" Stanley S. Scott Oncology Grand Rounds, Louisiana State University Medical Center, New Orleans, Louisiana. August 2000
69. Invited Speaker, "Capecitabine in the treatment of breast cancer." Grand Rounds, University of Tennessee at Knoxville, Knoxville, Tennessee. 1999
70. Platform Presentation, "Phase I and pharmacokinetic (Pk) study of Lu79553, a novel bis-naphthalamide on a daily X 5 schedule." American Society of Clinical Oncology Annual Meeting, Los Angeles, California. May 1998
71. Plenary Presentation, "Paclitaxel and Capecitabine: A synergistic combination?" Chemotherapy Foundation Symposium XVI Innovative Cancer Therapy for Tomorrow, New York, New York. November 1998
72. Invited Speaker, "The discovery of New Drugs for the Treatment of Cancer: The Process; What is New?" VI Jornadas del Interior, Cordoba, Argentina. 1998
73. Invited Speaker, "Non Small Cell Lung Cancer: Where are we? Where are we going?" VI Jornadas del Interior, Cordoba, Argentina. 1998
74. Invited Speaker, Treatment of advanced lung cancer. Guest Professor. XII Oncology Centroamerican and Caribbean Congress and Integrated Congresses. Antigua, Guatemala. October 1998
75. Invited Speaker, "The Development of Anticancer Agents." Guest Professor, XII Oncology Centroamerican and Caribbean Congress and Integrated Congresses, Antigua, Guatemala. October 1998
76. Invited Speaker, "Chemotherapy in Lung Cancer. New Perspectives?" Guest Professor, XIV meeting of the Mexican National Cancer Institute, Merida, Yucatan. 1997
77. Guest Professor, "Fluorinated Pyrimidines and Inhibitors of Thymidilate Synthase: New Agents and New Strategies.", New drugs and therapeutic combinations in gastrointestinal tumors symposium, Buenos Aires, Argentina. 1997

78. Master Conference, "New Drugs in the Treatment of Cancer." XIV Meeting Mexican national Cancer Institute, Merida, Yucatan. 1997
79. Guest Professor, "New Drugs: An update.", XIII Congreso Argentino de Oncología Clínica, Buenos Aires, Argentina. October 1997
80. Guest Professor, "CPT-11.", XIII Congreso Argentino de Oncología Clínica, Buenos Aires, Argentina. October 1997
81. Plenary Session, "Irinotecan for Metastatic Colorectal Cancer After Treatment with 5FU, Efficacy and Toxicity." X Brazilian Congress of Clinical Oncology, Sao Paulo, Brazil. June 1997
82. Guest Professor, "Irinotecan: Toxicity and Efficacy." New drugs and therapeutic combinations in gastrointestinal tumors symposium, Buenos Aires, Argentina. March 1997
83. Master Conference, "Non Small Cell Lung Cancer. Where are we? Where are we going?". Mexican Society of Oncological Studies, Mexico City. Mexico. 1997
84. Guest Professor, "Medical treatment of Colorectal Cancer.", Internacional Course of Gastroenterology, Monterrey, Mexico. 1996
85. Guest Professor, "Pancreatic cancer, Chemotherapy, Radiotherapy or Both.", Internacional Course of Gastroenterology. 1996
86. Invited Speaker."Phase I and II trials of Gemcitabine in pancreatic, lung and other cancers." Grand Rounds, Sylvester Comprehensive Cancer Center, Miami, Florida. 1996
87. Guest Professor, "New Strategies in Gastro-intestinal Tract Cancers.", XI Oncology Centroamerican and Caribbean Congress and Integrated Congresses, Santo Domingo Dominican Republic. October 1996
88. Guest Professor, "New Drugs in the Fight Against Cancer." XI Oncology Centroamerican and Caribbean Congress and Integrated Congresses, Santo Domingo Dominican Republic. October 1996
89. Invited Speaker, "The 5- α Reductase deficiency syndrome: From pseudo-Hermafroditism to cancer prevention." GU committee, Southwest Oncology Group Meeting, Phoenix Arizona. 1995
90. Invited Speaker, "Incomplete androgen insensitivity, first cases studied in the Dominican Republic." IV Student Congress on Scientific Research, San Juan, Puerto Rico. 1986

Research Interest

Thoracic Malignancies

Drug Development - Phase I/II Clinical trials

Experimental Therapeutics/Translational Research

Molecular Targeted Therapy

Modulation of Anticancer Drugs through Molecular Pharmacology

Description of Current Research Projects

Focus/Project 1: The identification of subgroups of patients who are exquisitely responsive to treatment with DNA breaking and molecularly targeted agents has led to the identification of pathways that are critical for DNA repair and of mutations that drive the malignancies. Dr Villalona's laboratory is conducting research in tumor specimens of patients undergoing surgery (breast, colon, ovarian, lung, prostatic, pancreatic and cervical cancer) to evaluate for an all inclusive method assessing the functionality of the Fanconi Anemia/BRCA pathway. An immunofluorescence-based test (FATSI) in paraffin embedded tissues, which could potentially lead to the identification of patients most likely to respond to DNA breaking agents or to agents inhibiting compensatory mechanisms of repair, has been developed and made available to the CLIA compliant Pathology Molecular core of OSUCCC. Collaboration with the NCI to test the effect of the PARP inhibitor ABT-888 in cancer cells and

fibroblasts deficient in this pathway and to identify synergistic molecules is underway. A human trial using selection by this strategy to treat cancer patients was activated and supported through a grant by the NCI/CTEP ACTNOW program. An NCI R01 to further explore this concept was awarded. 600 + pts have been screened, 60 pts have been enrolled in the therapeutic portion of the study. An R21 to study this concept in lung cancer was subsequently funded (Dr. Duan PI).

Focus Project 2: P53 mutation is one of the most common abnormalities in human malignancies. The laboratory of Dr. Villalona investigates potential strategies to restore the tumor suppressor activity of this gene. This includes the development of two mouse models of p53 mutations expressed exclusively in the lung through transgenic technology, and pioneering investigations in the role of the novel gene Pirh2 in P53 activation and the small molecule PRIMA 1 as promoter of p53-dependent apoptosis through regulation of microRNA 34a. Therapeutic interventions with PRIMA 1 to restore P53 function are being conducted on Dr. Villalona's laboratory. An R01 in this subject has been submitted.